Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 3879. Отображено 100.
12-01-2012 дата публикации

Blood coagulation inducing polymer hydrogel

Номер: US20120009242A1
Автор: Adam Behrens, Bartley P. Griffith, Brendan J. Casey, Peter Kofinas, Trevor A. Snyder
Принадлежит: University of Maryland at Baltimore, UNIVERSITY OF MARYLAND AT COLLEGE PARK

The present application is drawn to a synthetic, polymer hydrogel-based material, which is able to actively induce the body's natural hemostatic coagulation process in blood or acellular plasma. The present invention provides the development of a primary amine containing polymer hydrogel capable of inducing blood coagulation and delivering therapeutics for hemostatic or wound care applications, and a method of forming such a primary amine containing polymer hydrogel capable of inducing the blood coagulation process. The primary amine containing polymer hydrogel is able to achieve the same end result as biological-based hemostatics, without the innate risk of disease transmission or immunological response, and at a fraction of the price. Furthermore, due to its inherent hydrogel-based design the material has the capability of arresting blood loss while simultaneously delivering therapeutics in a controlled manner, potentially revolutionizing the way in which wounds are treated.

Подробнее
Номер записи: 1
26-01-2012 дата публикации

Bone cement system for bone augmentation

Номер: US20120022542A1
Автор: Andreas Boger, Christoph Sattig, Stefan Deusser
Принадлежит: Synthes USA LLC

A bone cement is provided that includes a solid component and a liquid component. The solid component and liquid component are mixed together to form the bone cement. After completion of the solid and liquid component mixing, the bone cement has an initial viscosity effective for manual application or manual injection onto or into a targeted anatomical location, e.g., bone, and the cement has stable viscosity range that over both time and temperature is effective for uniformly filling the targeted anatomical location, for example an osteoporotic bone or a fractured vertebral body, with minimal to no leakage of the cement from the targeted anatomical location. Additionally, both the initial viscosity and the stable viscosity of the bone cement are within a range that renders the bone cement effective for injection with a manually operated syringe or multiple syringes.

Подробнее
Номер записи: 2
09-02-2012 дата публикации

Bone cement composition, bone cement composition kit and forming method of bone cement hardened material

Номер: US20120035296A1
Автор: Hiroaki Nishii, Koji Goto, Masashi Imamura, Takashi Nakamura, Takehiro Shibuya, Tokuo Suita, Yoshimichi Ueda
Принадлежит: Ishihara Sangyo Kaisha Ltd, KYOTO UNIVERSITY

The invention has as its objects the provision of a bone cement composition, a bone cement composition kit for obtaining the bone cement composition, and a production method of a bone cement hardened material, which are short in doughing time that is a time required to become a state in which a good handling operation can be conducted, and have consequently capable of achieving a high working efficiency by shortening the time required before the handling operation is started. The bone cement composition of the invention contains large-diameter (meth)acrylate polymer particles having an average particle diameter of 10 to 60 μm, small-diameter (meth)acrylate polymer particles having an average particle diameter of 0.1 to 2.0 μm, a (meth)acrylate monomer and a polymerization initiator, wherein the content of the small-diameter (meth)acrylate polymer particles is 5 to 30% by mass based on the total mass of the small-diameter (meth)acrylate polymer particles and the large-diameter (meth)acrylate polymer particles.

Подробнее
Номер записи: 3
01-03-2012 дата публикации

Adhesive structure with stiff protrusions on adhesive surface

Номер: US20120052234A1
Автор: Audrey Yoke Yee HO, Chee Tiong Lim, Hong Yee Low, Isabel Rodriguez, Kevin Cooper, Murty N. Vyakarnam, Noha ELMOUELHI, Sriram Natarajan
Принадлежит: Advanced Technologies and Regenerative Medicine LLC, Agency for Science Technology and Research Singapore

An adhesive structure is provided comprising a surface from which extend substantially cylindrical protrusions comprising a stiff resin having a Young's modulus of greater than 17 MPa. The protrusions are of sufficiently low diameter to promote adhesion by physical attractive forces, e.g., Van der Waals attractive forces, as measured by shear adhesion between the adhesive structure and a target surface. A method for preparing the structure is provided as well as a combination of the adhesive structure and target surface.

Подробнее
Номер записи: 4
05-04-2012 дата публикации

Antimicrobial adhesive system

Номер: US20120083536A1
Автор: David D. Cox, Leland W. Annett, Robert E. Lund
Принадлежит: Individual

An adhesive composition having dispersed therein a broad spectrum antimicrobial agent for use in medical applications, such as an adhesive for surgical drapes, wound dressings and tapes, is provided. The adhesive is composed of acrylic polymers, tackifiers and a preferred antimicrobial agent, diiodomethyl-p-tolylsulfone. The subject adhesive composition may be formulated as either an essentially solventless hot melt, or as a solvent based system wherein an emulsion of the antimicrobial agent and the removal of excess solvent is avoided.

Подробнее
Номер записи: 5
10-05-2012 дата публикации

Composite bone cements with a pmma matrix, containing bioactive antibacterial glasses or glassceramics

Номер: US20120115981A1
Автор: Alessandro Bistolfi, Alessandro Masse, Enrica Verne', Giovanni Maina, Marta Miola, Maurizio Crova, Sara Ferraris
Принадлежит: POLITECNICO DI TORINO, Universita degli Studi di Torino

A bone cement comprising an acrylic polymeric component and an inorganic component comprising a bioactive glass or glass-ceramic, comprising at least one metal oxide having an anti-bacterial activity, wherein said glass or glass-ceramic component is adapted to release ions of said metal in contact with physiological fluids. The bone cement performs a sustained antibacterial action, also promoting binding with the tissues with which it is contacted, and it is advantageously employed in the fixation of orthopaedic prostheses, in the production of temporary prostheses and in spinal surgery.

Подробнее
Номер записи: 6
16-08-2012 дата публикации

Reinforced surgical adhesives and sealants and their in-situ application

Номер: US20120209319A1
Автор: Havazelet Bianco-Peled, Ohad Kimhi
Принадлежит: Technion Research and Development Foundation Ltd

In situ application of reinforced adhesive: applying uncured and curable matter to a surface, applying biocompatible inert reinforcing agent comprising at least one curing agent to the uncured composition; allowing curing within subject, cured composition together with the added reinforcing agent being configured to have improved mechanical support and strength.

Подробнее
Номер записи: 7
27-09-2012 дата публикации

Reversible oral adhesive gel

Номер: US20120244103A1
Автор: George John Orban, John Alexander Staton, Robert J. Davis
Принадлежит: Individual

The invention relates to a reversible oral adhesive gel. The reversible oral adhesive gel is suitable for application to lips to inhibit oral (mouth) breathing and to promote nasal breathing and thereby prevent or ameliorate snoring and to correct other respiratory problems.

Подробнее
Номер записи: 8
31-01-2013 дата публикации

Kit and method for producing bone cement

Номер: US20130030058A1
Автор: Hubert Büchner, Sebastian Vogt
Принадлежит: HERAEUS MEDICAL GMBH

A kit for producing bone cement includes at least one paste A and one paste B. Paste A contains at least one monomer (a1) for radical polymerization; at least one polymer (a2) insoluble in monomer (a1); at least one polymer (a3) soluble in monomer (a1); and at least one radical polymerization initiator (a4). The weight ratio of the at least one polymer (a2) to the at least one polymer (a3) is at least 2 to 1. Paste B contains at least one monomer (b1) for radical polymerization; at least one polymer (b2) and at least one accelerator (b3) soluble in monomer (b1); and optionally a polymer (b4) insoluble in monomer (b 1 ). The maximum quantity of polymer (b4) is 5% by weight, relative to the total weight of paste B. The weight ratio of polymer (b4) to the at least one polymer (b2) is no more than 0.2.

Подробнее
Номер записи: 9
25-04-2013 дата публикации

FUNCTIONALIZED ADHESIVE FOR MEDICAL DEVICES

Номер: US20130098550A1
Автор: Hadba Robert Ahmad, Sargeant Tim, Stopek Joshua
Принадлежит: COVIDIEN LP

A method for adhering a medical device to biological tissue includes adhering an adhesive composition having a plurality of reactive members of a specific binding pair to tissue which has a plurality of complementary reactive members of the specific binding pair via click chemistry. 1. A method for adhering a medical device to biological tissue comprising:providing a bifunctional adhesive composition having a plurality of reactive members of a first specific binding pair and a plurality of reactive members of a second specific binding pair;providing tissue with a plurality of complementary reactive members of the first specific binding pair;contacting the adhesive composition with the biological tissue, wherein upon contact of the reactive members of the first specific binding pair with the complimentary reactive members of the first specific binding pair associated with the tissue, covalent bonds are formed between the reactive members and the complementary reactive members of the first specific binding pair, thus adhering the adhesive to the tissue;providing a medical device having a plurality of complementary reactive members of the second specific binding pair;contacting the medical device with the adhesive, wherein upon contact of the reactive members of the second specific binding pair with the complimentary reactive members of the second specific binding pair associated with the device, covalent bonds are formed between the reactive members and the complementary reactive members of the second specific binding pair, thus adhering the device to the adhesive composition.2. The method for adhering a medical device to biological tissue according to wherein the members of the first specific binding pair bind to one another via a reaction selected from the group consisting of Huisgen cycloaddition reaction claim 1 , a Diels-Alder reaction and a thiol-ene reaction and the members of the second specific binding pair bind to one another via a reaction selected from the ...

Подробнее
Номер записи: 10
16-05-2013 дата публикации

TRANSDERMAL ADHESIVE COMPOSITIONS, DEVICES AND METHODS

Номер: US20130122079A1
Автор: DiZio James P., Johnson Elizabeth E., Preszier Prince Amy, Wu Zheng Zhi
Принадлежит:

A stable transdermal adhesive composition comprising: an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; and at least one pharmaceutically active compound which is susceptible to oxidative degradation; wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive, methods of making the composition, a transdermal drug delivery device using the composition, methods of making the device, and methods of delivery the pharmaceutically active compound are provided. 1. A transdermal adhesive composition comprising:an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; andat least one pharmaceutically active compound which is susceptible to oxidative degradation;wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive; andwherein any free radical initiator, if present in the adhesive, is present at a level of less than 20 ppm, based upon the total weight of the adhesive.2. A transdermal adhesive composition comprising:an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; and(S)—N-ethyl-N-methyl-3-[1-(dimethylamino)ethyl]phenyl carbamate or a pharmaceutically acceptable salt thereof;wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive.3. The composition of claim 2 , wherein any free radical initiator claim 2 , if present in the adhesive claim 2 , is present at a level of less than 20 ppm ...

Подробнее
Номер записи: 11
11-07-2013 дата публикации

THERAPEUTIC AGENT FOR PULMONARY EMPHYSEMA

Номер: US20130178426A1
Автор: Anzai Takao, Nogawa Atsuhiko, Tada Yuichi
Принадлежит: TERUMO KABUSHIKI KAISHA

The invention has as its object the provision of a medicine capable of reducing a volume of emphysema-suffering pulmonary alveoli or alveolar sacs by means of a respiratory region volume inhibitor containing a coating film formation as a main component and capable of forming a coating film in a respiratory region, characterized by being used in such a way that the coating film-forming component is administered to an emphysema-suffering pulmonary alveolar parenchyma in a human-respiratory region in an amount of 0.004 to 200 g/application, preferably 0.07 to 20 g/application and more preferably 0.5 to 5 g/application on each occasion. 1. A respiratory region volume inhibitor containing a coating film-forming component as a main component and capable of forming a coating film in a respiratory region ,being used in such a way that the coating film-forming component is administered to an emphysema-suffering pulmonary alveolar parenchyma in a human-respiratory region in an amount of 0.004 to 200 g on each occasion.2. The respiratory region volume inhibitor according to claim 1 ,wherein the coating film-forming component is configured such that a balloon-shaped closed pouch made of the coating film is formed in intimate contact with an inner surface of the respiratory region along an inner peripheral surface of the respiratory region in response to an external stimulation, andthe balloon-shaped closed pouch is shrunk by reducing a pressure inside the balloon-shaped closed pouch from outside of the respiratory region.3. The respiratory region volume inhibitor according to claim 2 ,wherein the external stimulation includes an external stimulation component.4. The respiratory region volume inhibitor according to claim 1 ,wherein the coating film-forming component contains a tacky polymer, andthe external stimulation component is made of a reactive gas.5. The respiratory region volume inhibitor according to claim 1 ,wherein the coating film-forming component contains polymer ...

Подробнее
Номер записи: 12
25-07-2013 дата публикации

Light Activated Composite Tissue Adhesives

Номер: US20130190245A1
Автор: Soltz Barbara A., Soltz Robert
Принадлежит:

A light activated collagen-flavin composite layer incorporating riboflavin is applied as treatment for infected lesions caused by bacteria and as the consequence of surgical procedures. These composites have also been found to be strong tissue adhesives that are effective in closing and sealing wounds, fixation of grafts/ implants and anastomoses. Advantages include speed of closure, reduced infection due to the elimination of foreign matter, evidence of accelerated wound healing and the ease of use in complex surgery, especially when watertight seals, limited access or small repair size are important factors. The riboflavin in the collagen layer is exposed to light (e.g., light having a wavelength between 360-375 nm or 440-480 nm), decomposing the riboflavin to form reactive oxygen species (ROS). Strong crosslinks between the collagen composite and tissue results. In addition, similar exposures eradicate pathogens in the wound is eradicated resulting in a sterile wound. In other examples, the composite film may instead contain lumichrome or lumiflavin. 1. A composition , comprising:gelatin, wherein a concentration of the gelatin in the composition is in a range of 20% (w/v) to 50% (w/v);collagen, wherein a concentration of the collagen in the composition is in a range of 10% to 40% (w/v); anda chromophore that produces a reactive oxygen species upon exposure to electromagnetic radiation.2. A composition in accordance with claim 1 , wherein the chromophore includes riboflavin.3. A composition in accordance with claim 1 , wherein a concentration of the riboflavin in the composition is within a range of 0.1% to 2.0% (w/v).4. A composition in accordance with claim 1 , wherein the concentration of the riboflavin in the composition is substantially equal to 1.0%.51. A composition in accordance claim 1 , wherein the chromophore includes lumiflavin.6. A composition in accordance with claim 1 , wherein the chromophore includes lumichrome.7. A composition in accordance with ...

Подробнее
Номер записи: 13
19-09-2013 дата публикации

High Adhesion Antimicrobial Skin Prep Solution and Related Methods

Номер: US20130239977A1
Автор: JR. James E., McGuire
Принадлежит: entrotech life sciences, inc.

Antimicrobial skin prep solutions of the invention comprise: a major amount of at least one organic solvent, wherein at least about 80% by weight based on total weight of the solvent comprises at least one fugitive organic solvent; an antimicrobially effective amount of at least one antimicrobial agent; and an amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution, wherein the at least one adhesive is distinct from the at least one antimicrobial agent and is a liquid at room temperature. Coated substrates, applicators, and related methods are also disclosed. 1. An antimicrobial skin prep solution comprising:a major amount of at least one organic solvent, wherein at least about 80% by weight based on total weight of the solvent comprises at least one fugitive organic solvent;an antimicrobially effective amount of at least one antimicrobial agent; andan amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution,wherein the at least one adhesive is distinct from the at least one antimicrobial agent and is a liquid at room temperature.2. The antimicrobial skin prep solution of claim 1 , wherein the amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution is about 2% by weight of the skin prep solution.3. The antimicrobial skin prep solution of claim 1 , wherein the amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution is about 5.5% by weight of the skin prep solution.4. The antimicrobial skin prep solution of claim 1 , wherein the at least one adhesive is a hydrogel in the skin prep solution.5. The antimicrobial skin prep solution of claim 1 , wherein the ...

Подробнее
Номер записи: 14
03-10-2013 дата публикации

Methods, Materials and Apparatus for Treating Bone and Other Tissue

Номер: US20130261217A1
Автор: BEYAR Mordechay, GLOBERMAN Oren, Shavit Ronen, Wachsler-Avrahami Hila
Принадлежит: DePuy Spine, Inc.

A bone cement comprising a first component and a second component, wherein contacting the first component and the second component produces a mixture which attains a high viscosity an initial period and the viscosity of the mixture remains relatively stable for a working time of at least 5 minutes after the initial setting period, and the mixture is suitable for in-vivo use. 1. A bone cement comprising:a first component; anda second component,wherein, contacting the first component and the second component produces a mixture which attains a viscosity greater than 500 Pascal seconds within an initial period,wherein the viscosity of the mixture remains between 500 and 2000 Pascal seconds for a working time of at least 5 minutes after the initial period, andwherein the mixture is suitable for in-vivo use.2. The bone cement of claim 1 , wherein the working time is at least 8 minutes long.3. The bone cement of claim 1 , wherein the initial period is less than 3 minutes.4. The bone cement of claim 1 , wherein the initial period does not exceed 1 minute.5. The bone cement of claim 1 , wherein the mixture solidifies after the working time.6. The bone cement of claim 1 , wherein the initial period is less than 3 minutes and the mixture solidifies after the working time7. The bone cement of claim 6 , wherein the first component includes PMMA and Barium Sulfate.8. The bone cement of claim 6 , wherein the second component includes MMA and DMPT.9. The bone cement of claim 6 , wherein the first component includes PMMA claim 6 , Barium 30 Sulfate claim 6 , and Benzoyl Peroxide claim 6 , and wherein the second component includes MMA claim 6 , DMPT claim 6 , and Hydroquinone.10. The bone cement of claim 1 , wherein the viscosity of greater than 500 Pascal-second results at least partly from a polymerization reaction.11. A bone cement comprising:a first component; anda second component,wherein, contacting the first component and the second component produces a mixture which attains a ...

Подробнее
Номер записи: 15
10-10-2013 дата публикации

POST IRRADIATION SHELF-STABLE DUAL PASTE DIRECT INJECTABLE BONE CEMENT PRECURSOR SYSTEMS AND METHODS OF MAKING SAME

Номер: US20130264244A1
Автор: "OMahony Donal", Garigapati Venkat R., Hess Brian, Murphy Matthew E., Sun Wai Adrian
Принадлежит:

The present invention relates to a bone cement precursor system that is presented in the form of two shelf-stable pastes which have been terminally sterilized and are held in separate containers during product transport and storage. When the product is used during surgery, these pastes inject to a site of application through a static mixing device by the action of applied injection force. When the two pastes are mixed, they start to react to each other while injecting out. The resulting composition is highly biocompatible, osteoconductive, injectable, rapid setting and bioresorbable, and is useful in connection with bone repair procedures, for example, in the craniomaxillofacial, trauma and orthopedic areas. 1. A bone cement precursor system comprising:a first container containing an acidic aqueous paste comprising monocalcium phosphate monohydrate (MCPM) and dicalcium phosphate anhydrous (DCPA), citric acid, water, glycerol, polyvinyl pyrrolidone (PVP) and polyethylene glycol (PEG), anda second container containing an alkaline non-aqueous paste comprising at least one basic calcium phosphate mineral, at least one paste stabilizing agent, a surfactant and a solvent.2. The bone cement precursor system of claim 1 , wherein said system is shelf-stable post terminal sterilization.3. The bone cement of claim 2 , wherein said terminal sterilization is gamma irradiation.4. The bone cement precursor system of claim 1 , wherein the mean particle size of said monocalcium phosphate monohydrate (MCPM) and dicalcium phosphate anhydrous (DCPA) is between about 1 μm to about 90 μm.5. The bone cement precursor system of claim 1 , wherein the amount of said monocalcium phosphate monohydrate (MCPM) and dicalcium phosphate anhydrous (DCPA) present in said acidic aqueous paste is between about 5% w/w to about 65% w/w based on the total weight of said acidic aqueous paste.6. The bone cement precursor system of claim 4 , wherein the mean particle size of said monocalcium phosphate ...

Подробнее
Номер записи: 16
10-10-2013 дата публикации

Methods of building a body portion

Номер: US20130267026A1
Автор: Peter M. Bonutti
Принадлежит: P Tech LLC

An improved method of implanting cells in the body of a patient includes positioning viable cells on a support structure. One or more blood vessels may be connected with the support structure to provide a flow of blood through the support structure. A support structure may be positioned at any desired location in a patient's body. The support structure may be configured to replace an entire organ or a portion of an organ. An organ or portion of an organ may be removed from a body cells and/or other tissue is removed to leave a collagen matrix support structure having a configuration corresponding to the configuration of the organ or portion of an organ. Alternatively, a synthetic support structure may be formed. The synthetic support structure may have a configuration corresponding to a configuration of an entire organ or only a portion of an organ.

Подробнее
Номер записи: 17
24-10-2013 дата публикации

BIOLOGIC BONDING AGENT

Номер: US20130281549A1
Автор: Bonutti Peter M.
Принадлежит:

A sterile biofilm could be engineered to isolate the glue-like substance while eliminating the adverse properties of the bacteria. The resulting sterile glue-like substance would be used to help the cells stick to the support structure. The engineered biofilm could be added to the support structure in the laboratory that produces the support structure or just prior to the addition of the cells by the user. Alternatively, the biofilm and support structure could be combined intra-corporally. This biofilm also could be used as an independent polysaccharide based adhesive with mild to moderate adhesion forces. The biofilm could serve as a surgical adhesion or grouting for cells, for tissue fixation (soft tissue to soft tissue, soft tissue to bone, etc.) and as a sealant. The biofilm could be used in conjunction with other implants and devices. The biofilm could be used to coat a stent. 1. A biologic bonding agent comprising:an engineered adhesive derived at least in part from a bacterial source; andthe adhesive being configured to be collected, processed to be substantially free of viable bacteria, and placed in a container,wherein adhesive properties of the bacterial source are substantially maintained.2. The bonding agent of claim 1 , wherein the bacterial source includes biofilm.3. The bonding agent of claim 1 , wherein at least a portion of the adhesive is polysaccharide based.4. The bonding agent of claim 1 , wherein the adhesive is configured to be coated on or impregnated in at least a portion of an implant.5. The bonding agent of claim 1 , wherein at least a portion of the adhesive is biodegradable.6. The bonding agent of claim 1 , wherein the adhesive is configured to be coated on or impregnated in at least a portion of a stent.7. The bonding agent of claim 1 , wherein the adhesive is configured to be applied to at least a portion of a collagen material.8. The bonding agent of claim 1 , wherein the adhesive is configured to promote attachment of cells to a ...

Подробнее
Номер записи: 18
07-11-2013 дата публикации

MEDICAL ADHESIVE FILM

Номер: US20130295345A1
Автор: GUAN Hongxia, PEI Fuxing, Peng Bo, SONG Jiuhong
Принадлежит:

An adhesive film including an upper surface including a developing reference axis. The adhesive film is simple in structure, accurate in positioning, and convenient for practice. 12. An adhesive film , comprising an upper surface comprising a developing reference axis ().223. The adhesive film of claim 1 , wherein the developing reference axis () is provided with reference numbers ().3. The adhesive film of claim 2 , wherein{'b': 1', '1, 'i': a,', 'b, 'the adhesive film comprises an uppermost adhesive film and a plurality of layers of inner adhesive films (. . . );'}{'b': 1', '1, 'i': a,', 'b, 'the inner adhesive films (. . . ) are disposed beneath the uppermost adhesive film;'}{'b': 2', '2', '2, 'i': a,', 'b, 'each of the inner adhesive films comprises an upper surface comprising a reference axis (. . . ) being the same as the developing reference axis () arranged on the uppermost adhesive film; and'}{'b': 2', '2, 'i': a,', 'b, 'the reference axis (. . . ) arranged on each of the inner adhesive films superposes with one another.'}4221133a,ba,ba,b. The adhesive film of claim 3 , wherein the reference axis (. . . ) arranged on each inner adhesive film (. . . ) is provided with reference numbers (. . . ).52. The adhesive film of claim 1 , wherein the developing reference axis () is in a grid structure formed by arranging transverse lines and vertical lines at equal intervalss between each other.622a,b. The adhesive film of claim 3 , wherein the reference axis (. . . ) arranged on each inner adhesive film is in a grid structure formed by arranging transverse lines and vertical lines at equal intervals between each other.722a,b. The adhesive film of claim 4 , wherein the reference axis (. . . ) arranged on each inner adhesive film is in a grid structure formed by arranging transverse lines and vertical lines at equal intervals between each other.82. The adhesive film of claim 5 , wherein vertical lines and/ or transverse lines of the developing reference axis () ...

Подробнее
Номер записи: 19
21-11-2013 дата публикации

COMPOSITION CONTAINING INJECTABLE SELF-HARDENED APATITE CEMENT

Номер: US20130309214A1
Автор: Fazan Fazilah Binti, Ibrahim Shirin Binti, Kader Bashah Nor Shahida Binti, Sabudin Salina, Sahid Sudirman Bin, Wan Sulaiman Wan Ruzaini Bin
Принадлежит: SIRIM Berhad

A method of producing an injectable calcium phosphate paste by a process in which calcium phosphate precursors are mixed with the setting fluids to form a self-hardened apatite cement is disclosed. The produced apatite cement is biocompatible, bioactive and biodegradable in the body. The pH value of said apatite cement is approximately 7 with compressive strength between 10-30 MPa and the setting process will not generate.temperature >37° C. The self-hardened apatite (SHA) cement is found to be bioresorbable and can be used for bone fillers, fixation of broken bones or artificial joints in human and also appropriate for use as a delivery vehicle. 1. A composition of injectable self-hardened apatite cement comprising:{'sub': 3', '4', '2', '4', '4', '2, 'a. a main matrix comprising tri-calcium phosphate (TCP; Ca(PO)) and tetra-calcium phosphate (TTCP; Ca(PO)O),'}{'sub': 2', '3', '6', '8', '7', '6', '5', '3', '7', '2, 'b. hardening agents comprising sodium carbonate (NaCO), citric acid, (CHO) and sodium citrate (CHNaO.2HO),'}c. setting fluids andd. filler and pH stabiliser.2. The composition according to wherein the filler and pH stabiliser is hydroxyapatite (Ca(PO)(OH)).3. The composition according to claim 1 , wherein the weight ratio of tri-calcium phosphate to tetra-calcium phosphate is in the range of 45:55 to 55:45.4. The composition according to claim 1 , wherein said sodium carbonate is present in an amount ranging from about 5 to 10 weight percentage.5. The composition according to claim 1 , wherein said citric acid is present in an amount ranging from about 20 to 30 weight percentage.6. The composition according to claim 1 , wherein said sodium citrate is present in an amount ranging from about 5 to 10 weight percentage.7. The composition according to claim 1 , wherein said filler and/or pH stabiliser is present in an amount ranging from about 1 to 5 weight percentage.8. The composition according to claim 1 , wherein the setting fluids are selected from a ...

Подробнее
Номер записи: 20
05-12-2013 дата публикации

TISSUE ADHESIVE BASED ON NITROGEN-MODIFIED ASPARTATES

Номер: US20130325062A1
Автор: Eggert Christoph, Heckroth Heike
Принадлежит: Bayer Intellectual Property GmbH

The invention relates to a polyurea system comprising as component A) isocyanate-functional prepolymers which can be obtained by reacting aliphatic isocyanates A1) with polyols A2) that can have a number-average molecular weight of =400 g/mol and an average OH functionality of 2 to 6 in particular; and as component B) amino-functional aspartic acid esters of the general formula (I) in which X is an organic group containing a secondary amino function, R1, R2 are the same or different organic groups that do not have Zerewitinoff-active hydrogen, and n is a whole number of at least 2, in particular for sealing, bonding, gluing, or covering cell tissue. The invention also relates to a metering system for the polyurea system according to the invention. 115-. (canceled)18. The polyurea system as claimed in claim 17 , wherein Rand Rin each case independently of one another or simultaneously are a linear or branched saturated organic radical optionally also substituted in the chain with heteroatoms.19. The polyurea system as claimed in claim 16 , wherein the radicals Rand Rin each case independently of one another are linear or branched C1 to C10 organic radicals.20. The polyurea system as claimed in claim 17 , wherein Rand Rin each case independently of one another or simultaneously are a linear or branched claim 17 , saturated claim 17 , aliphatic C2 to C6 claim 17 , and the radicals Rand Rin each case independently of one another are linear or branched C2 to C4 aliphatic hydrocarbon radicals.21. The polyurea system as claimed in claim 16 , wherein the polyols A2) contain polyesterpolyols and/or polyester-polyether-polyols and/or polyetherpolyols with an ethylene oxide fraction between 60 and 90% by weight.22. The polyurea system as claimed in claim 16 , wherein the polyols A2) contain polyester-polyether-polyols and/or polyetherpolyols with an ethylene oxide fraction between 60 and 90% by weight.23. The polyurea system as claimed in claim 16 , wherein the polyols A2) ...

Подробнее
Номер записи: 21
12-12-2013 дата публикации

Means for Controlled Sealing of Endovascular Devices

Номер: US20130331929A1
Автор: Ashish Sudhir Mitra, Ben Colin Bobillier, Pak Man Victor Wong
Принадлежит: Endoluminal Sciences Pty Ltd

Expandable sealing means for endoluminal devices have been developed for controlled activation. The devices have the benefits of a low profile mechanism (for both self-expanding and balloon-expanding prostheses), contained, not open, release of the material, active conformation to the “leak sites” such that leakage areas are filled without disrupting the physical and functional integrity of the prosthesis, and on-demand, controlled activation, that may not be pressure activated.

Подробнее
Номер записи: 22
26-12-2013 дата публикации

Cross-linked polymers and implants derived from electrophilically activated polyoxazoline

Номер: US20130345334A1
Автор: Jan Cornelis Maria Van Hest, Johannes Caspar Mathias Elizabeth Bender, Richard Hoogenboom
Принадлежит: Bender Analytical Holding BV

One aspect of the invention relates to a biocompatible, covalently cross-linked, polymer that is obtained by reacting an electrophilically activated polyoxazoline (EL-POX) with a nucleophilic cross-linking agent, said electrophilically activated POX comprising m electrophilic groups; and said nucleophilic cross-linking agent comprising n nucleophilic groups, wherein the m electrophilic groups are capable of reaction with the n nucleophilic groups to form covalent bonds; wherein m≧2, n≧2 and m+n≧5; wherein at least one of the m electrophilic groups is a pendant electrophilic group and/or wherein m≧3; and wherein the EL-POX comprises an excess amount of electrophilic groups relative to the amount of nucleophilic groups contained in the nucleophilic cross-linking agent. The invention further relates to biocompatible medical products comprising such a cross-linked POX-polymer. Also provided is a kit for producing a biocompatible, cross-linked POX-polymer. The invention further provides a tissue adhesive medical product comprising at least 1% by weight of dry matter of EL-POX, said EL-POX comprising at least 2 electrophilic groups, including at least one pendant electrophilic group. The polymers according to the invention have excellent implant and/or sealing characteristics.

Подробнее
Номер записи: 23
06-03-2014 дата публикации

TISSUE ADHESIVE WITH ACCELERATED CURING

Номер: US20140066981A1
Автор: Eggert Christoph, Heckroth Heike
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to a polyurea system encompassing as component A) isocyanate-functional prepolymers obtainable by reaction of aliphatic isocyanates A1) with polyols A2), which can in particular have a number average molecular weight of ≧400 g/mol and an average OH functionality of 2 to 6, as component B) amino-functional compounds of general formula (I) in which X is an organic residue comprising a tertiary amino function, having no Zerewitinoff active hydrogen, Ris a CH—COORresidue, in which Ris an organic residue having no Zerewitinoff active hydrogen, a linear or branched C1 to C4 alkyl residue, a cyclopentyl or cyclohexyl residue or H, Ris an organic residue having no Zerewitinoff active hydrogen, n is an integer ≧2 or ≦3, in particular for closing, binding, bonding or covering cell tissue, and to a metering system for the polyurea system according to the invention. 114-. (canceled)17. The polyurea system according to claim 16 , wherein R claim 16 , R claim 16 , Rare claim 16 , each independently of one another or simultaneously claim 16 , a linear or branched claim 16 , saturated organic residue that is optionally also substituted in the chain with heteroatoms claim 16 , in particular a linear or branched claim 16 , saturated claim 16 , aliphatic C1 to C10 claim 16 , preferably C2 to C8 and particularly preferably C2 to C6 hydrocarbon residue.18. The polyurea system according to claim 17 , wherein R claim 17 , R claim 17 , Rare claim 17 , each independently of one another or simultaneously claim 17 , a methyl claim 17 , ethyl claim 17 , propyl or butyl residue claim 17 , wherein at least one of R claim 17 , R claim 17 , Ris a methylene claim 17 , ethylene claim 17 , propylene or butylene residue.19. The polyurea system according to wherein R claim 15 , Rand optionally Rare claim 15 , each independently of one another or simultaneously claim 15 , a linear or branched C1 to C10 claim 15 , preferably C1 to C8 claim 15 , particularly preferably C2 to ...

Подробнее
Номер записи: 24
13-03-2014 дата публикации

POLY(OCTYLCYANOACRYLATE)-POLYISOBUTYLENE POLYMER CONETWORK, METHOD FOR THE PRODUCTION THEREOF AND USES THEREOF

Номер: US20140073743A1
Автор: Erdodi Gabor, Gasser Ryan, Kennedy Joseph, Tang Juay Seng
Принадлежит: THE UNIVERSITY OF AKRON

A polymer conetwork formed from the polymerization reaction of octyl-cyanoacrylate and a tri-telechelic star polymer comprising polyisobutylene terminated with cyanoacrylate groups (Ø(PIB-CA)), wherein the ratio of octyl cyanoacrylate to Ø(PIB-CA)is from about 10:1 to about 40:1. 1. A polymer conetwork formed from the polymerization reaction of:{'sub': 3', '3, 'octyl-cyanoacrylate and a tri-telechelic star polymer comprising polyisobutylene terminated with cyanoacrylate groups (Ø(PIB-CA)), wherein the ratio of octyl cyanoacrylate to Ø(PIB-CA)is from about 10:1 to about 40:1.'}2. The polymer conetwork according to claim 1 , wherein polymerization reaction is initiated by nucleophlic groups located on the surface to be covered by the polymer conetwork.3. The polymer conetwork according to claim 2 , wherein the surface to be covered is skin.4. The polymer conetwork according to any of to claim 2 , wherein the polymer conetwork exhibits higher elongation than a homopolymer of octyl cyanoacrylate.5. The polymer conetwork according to any of to claim 2 , wherein the polymer conetwork exhibits a strength of at least 5N and sufficient to maintain two pieces of skin together.6. Use of the polymer conetwork of for wound closure.7. Use of the polymer conetwork of for sealing surgical cuts and puncture wounds.8. Use of polymer conetwork of as an orthopedic sealant.9. Use of polymer conetwork of for repair of torn annulus. This application claims the benefit of U.S. Provisional Patent Application No. 61/441,813, filed Feb. 11, 2011 and claims the benefit of U.S. Provisional Patent Application No. 61/559,778, filed Nov. 15, 2011, both of which are hereby incorporated by reference.This invention relates to a polyisobutylene-based conetwork and, more particularly, to a poly(octyl cyanoacrylate)-polyisobutylene conetwork. In addition to the polymer conetwork, a method of producing the polymer conetwork is provided, as well as a number of uses for the polymer conetwork are disclosed. ...

Подробнее
Номер записи: 25
27-03-2014 дата публикации

Adhesive composition for soft tissues, adhesive composition for wound dressing or wound dressing composition

Номер: US20140086967A1
Автор: Hiroshi Naruse, Noriaki Asada
Принадлежит: Mitsui Chemicals Inc

The present invention provides an adhesive composition for soft tissues, an adhesive composition for wound dressing or a wound dressing composition, not only having low toxicity, low harmfulness and high adhesive strength but also being excellent in workability during application and being capable of forming films of excellent properties. The compound of the present invention is comprised a monomer (A), polymer particles (B) having a specific weight-average molecular weight and a specific volume mean particle diameter, and a polymerization initiator composition (C) containing an organoboron compound is produced.

Подробнее
Номер записи: 26
10-04-2014 дата публикации

BIORESORBABLE EMBOLIZATION MICROSPHERES

Номер: US20140099374A1
Автор: Golzarian Jafar, Weng Lihui
Принадлежит: Regents of the University of Minnesota

The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin. 1. An embolic material comprising at least one microsphere comprising carboxymethyl chitosan crosslinked with carboxymethyl cellulose.2. The embolic material of claim 1 , wherein the microsphere comprises a diameter between about 100 micrometers and about 1200 micrometers.3. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 300 micrometers and about 500 micrometers.4. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 100 micrometers and about 300 micrometers.5. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 700 micrometers and about 900 micrometers.6. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 900 micrometers and about 1200 micrometers.7. The embolic material of claim 1 , wherein the microsphere further comprises a therapeutic agent.8. The embolic material of claim 7 , wherein the therapeutic agent comprises a chemotherapeutic agent.9. The embolic material of claim 7 , wherein the therapeutic agent comprises at least one positively charged functional group.10. The embolic material of claim 7 , wherein the therapeutic agent comprises at least one of irinotecan claim 7 , ambroxol claim 7 , or doxorubicin.11. The embolic material of claim 7 , wherein a concentration of the therapeutic agent is between about 0.3 milligram of therapeutic agent per milligram of dry microsphere and about 0.75 milligram of therapeutic agent per milligram of dry microsphere.12. The embolic material of claim 1 , wherein ...

Подробнее
Номер записи: 27
04-01-2018 дата публикации

ONE COMPONENT FIBRIN GLUE COMPRISING A POLYMERIZATION INHIBITOR

Номер: US20180000982A1
Автор: DeAnglis Ashley, Doron Sivan, Nur Israel, Pilpel Yair, Zherdev Yuri
Принадлежит:

Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations. 113-. (canceled)14. A method for preparing a sealant at a surface comprising: providing a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 , 21 , 22 , 23 , 24 , and 25° C.; and applying the formulation to the surface under conditions which facilitate fibrin polymerization at the surface.15. The method of claim 14 , wherein the conditions comprise removing claim 14 , blocking claim 14 , neutralizing and/or diluting the GPRP peptide.1620-. (canceled)21. A method of healing claim 14 , sealing and/or reducing blood loss in a subject in need claim 14 , comprising applying to the subject an effective amount of a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 claim 14 , 21 claim 14 , 22 claim 14 , 23 claim 14 , 24 claim 14 , and 25° C.22. (canceled) The instant application contains a Sequence Listing, which is submitted concomitantly with this application via EFS-Web in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 22, 2013, is named “sequencelisting” and is 8 ...

Подробнее
Номер записи: 28
04-01-2018 дата публикации

HYDROGELS AND USE THEREOF IN ANASTOMOSIS PROCEDURES

Номер: US20180000983A1
Автор: Brandacher Gerald, Brat Gabriel, Grahammer Johanna, Schneider Joel, SMITH Daniel
Принадлежит:

This disclosure provides novel hydrogels that can undergo multiple gel-sol transitions and methods of making and using such hydrogels, particularly in anastomosis procedures. The peptide hydrogels comprising a fibrillar network of peptides that are in an amphiphilic β-hairpin conformation. The peptides comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel. Isolated peptides for making the disclosed hydrogels are provided, as are methods of using the peptide hydrogels in anastomosis procedures. 1. A peptide hydrogel comprising a fibrillar network of peptides , wherein:the hydrogel undergoes a gel-sol phase transition upon application of shear stress, and a sol-gel phase transition upon removal of the shear stress; andthe peptides are in an amphiphilic β-hairpin conformation and comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel.2. The peptide hydrogel of claim 1 , wherein:the amphiphilic β-hairpin conformation comprises a β-turn, a first β-strand, a second β-strand, a hydrophobic face, and a hydrophilic face;the assembly of the peptides in the fibrillar network comprises hydrophobic interactions between the hydrophobic faces of the peptides;the first β-strand comprises the photocaged glutamate residue, the second β-strand comprises a glycine residue, and the sidechains of the photocaged glutamate residue and the glycine residue are proximal to each other on the hydrophobic faces of the peptides; anduncaging the photocaged glutamate residues disrupts the hydrophobic interactions between the peptides by exposing negative charges of the glutamate residues, thereby disrupting the fibrillar network and triggering the irreversible gel-sol phase transition ...

Подробнее
Номер записи: 29
12-01-2017 дата публикации

IMPLANTATION DEVICES INCLUDING HYDROGEL FILAMENTS

Номер: US20170007264A1
Автор: Constant Michael J., Cruise Gregory M., Keeley Edward Michael, Tran Terrance T.
Принадлежит:

Described are devices for implantation comprising a hydrogel filament wherein the hydrogel filament includes a low molecular weight ethylenically unsaturated macromer, an ethylenically unsaturated monomer, and a visualization agent. Methods of making and using these devices are also described. 1. A device for implantation comprising:a hydrogel filament attached to a coupler wherein the coupler is attached to a pusher,wherein the hydrogel filament includes a low molecular weight ethylenically unsaturated macromer; an ethylenically unsaturated monomer; and a visualization agent,wherein said device contains no support members.2. The device of claim 1 , wherein said macromer has a molecular weight of about 100 grams/mole to about 5000 grams/mole.3. The device of claim 1 , wherein said macromer comprises polyethylene glycol claim 1 , propylene glycol claim 1 , poly(tetramethylene oxide) claim 1 , poly(ethylene glycol) diacrylamide claim 1 , poly(ethylene glycol) diacrylate claim 1 , poly(ethylene glycol) dimethacrylate claim 1 , derivatives thereof claim 1 , or combinations thereof.4. The device of claim 1 , wherein said visualization agent comprises an aromatic ring having a single unsaturation point and at least one iodine atom.5. The device of claim 1 , wherein said visualization agent comprises barium sulfate claim 1 , gadolinium claim 1 , or iron oxide.6. The device of claim 5 , wherein said visualization agent is barium sulfate.7. The device of claim 1 , wherein said ethylenically unsaturated monomer and said visualization agent comprise 2 claim 1 ,4 claim 1 ,6-triiodophenyl penta-4-enoate claim 1 , 5-acrylamido-2 claim 1 ,4 claim 1 ,6-triiodo-n claim 1 ,n′-bis-(2 claim 1 ,3 dihydroxypropyl) isophthalamide claim 1 , derivatives thereof claim 1 , or combinations thereof.8. The device of claim 1 , wherein said macromer and said monomer are crosslinked with N claim 1 ,N claim 1 ,N′ claim 1 ,N′-tetramethylethylenediamine claim 1 , ammonium persulfate claim 1 , ...

Подробнее
Номер записи: 30
14-01-2016 дата публикации

Adhesive Composition

Номер: US20160008505A1
Автор: Jensen Jarl, Keng Ta Kang, Ramjit Ravi
Принадлежит: EUROMED INC.

The present invention relates to an adhesive composition applicable to skin comprising: (i) a polar oil or fat including (a) at least one triglyceride and/or (b) at least one fatty acid of the formula R—COH, wherein R is a Cto Calkyl group; and (ii) at least one homopolymer, and/or copolymer. This invention also relates to a medical adhesive device including such adhesive composition. 2. (canceled)3. (canceled)4. (canceled)5. The adhesive composition of further comprising at least one tackifier.6. The adhesive composition of claim 5 , wherein the tackifier is selected from the group consisting of natural rosin claim 5 , modified rosin claim 5 , glycerol ester of natural rosin claim 5 , glycerol ester of modified rosin claim 5 , pentaerythritol ester of natural rosin claim 5 , pentaerythritol ester of modified rosin claim 5 , phenolic-modified terpene resin claim 5 , aliphatic petroleum hydrocarbon resin claim 5 , and cycloaliphatic resin.7. (canceled)8. (canceled)9. The adhesive composition of claim 1 , wherein the base polymer comprises at least two immiscible monomers.10. The adhesive composition of further comprising a hydrophilic fluid-absorbing gum or gel-thickener claim 1 , wherein the gum or gel-thickener is cationic claim 1 , anionic claim 1 , or non-ionic.11. The adhesive composition of claim 10 , wherein the gel-thickener is a water soluble or swellable hydrocolloid or a mixture thereof.12. The adhesive composition of claim 11 , wherein the gel-thickener is selected from a group consisting of carboxymethylcellulose claim 11 , hydroxyethylcellulose (HEC) claim 11 , hydroxypropylcellulose (HPC) claim 11 , pectin claim 11 , carrageenan claim 11 , and gelatin.13. A medical adhesive device comprising an adhesive composition comprising coconut oil claim 11 , a mineral oil claim 11 , and a base polymer.14. The adhesive device of claim 13 , wherein the adhesive composition further comprises a tackifier.15. The adhesive device of claim 14 , wherein the tackifier is ...

Подробнее
Номер записи: 31
11-01-2018 дата публикации

OSTOMY DEVICE

Номер: US20180008451A1
Автор: Stroebech Esben
Принадлежит:

Disclosed is an ostomy device with an adhesive wafer for attachment to a skin surface of a user and a collecting bag for collecting output from a stoma. The collecting bag is connected to the adhesive wafer, and the adhesive wafer has a through-going hole for accommodating the stoma of the user. The adhesive wafer includes a backing layer, a first switchable adhesive composition (), a second absorbent adhesive composition (), and a release liner. 125-. (canceled)26. An ostomy device comprising an adhesive wafer for attachment to a skin surface of a user , and a collecting bag connected to the adhesive wafer; the adhesive wafer having a through-going hole for accommodating the stoma of the user; and the adhesive wafer comprising a backing layer , a first switchable adhesive composition , a second absorbent adhesive composition , and a release liner , wherein the adhesive wafer has a central part adjacent to the hole for accommodating the stoma and a peripheral part adjacent to an edge of the adhesive wafer away from the hole , and wherein the second absorbent adhesive composition is located at least in the central part of the adhesive wafer , wherein the release liner is in contact with the first switchable adhesive composition in the peripheral part of the adhesive wafer , and wherein the release liner is in contact with the second absorbent adhesive composition in the central part of the adhesive wafer.27. The ostomy device according to claim 26 , wherein the switchable adhesive composition is switchable from a high-tack state with a first peel force to a lower-tack state with a second peel force.28. The ostomy device according to claim 27 , wherein the first peel force is higher than the second peel force.29. The ostomy device according to claim 27 , wherein the peel force is measured by a 90 degree peel test.30. The ostomy device according to claim 27 , wherein a reduction in peel force between the first peel force and the second peel force is at least 50%.31. ...

Подробнее
Номер записи: 32
08-01-2015 дата публикации

Temporary Embolization Using Inverse Thermosensitive Polymers

Номер: US20150010471A1
Автор: Raymond Jean, Schwarz Alexander
Принадлежит:

One aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter, and which compositions gel at or below body temperature. In certain embodiments of the methods of embolization, said composition further comprises a marker molecule, such as a dye, radiopaque, or an MRI-visible compound. 1. A method of temporarily embolizing a vascular site in a mammal , comprising the step of:introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, thereby temporarily embolizing a vascular site of said mammal.2. The method of claim 1 , wherein said mammal is a human.3. The method of claim 1 , wherein the transition temperature of said inverse thermosensitive polymer is between about 10 C and about 40 C.4. The method of claim 1 , wherein the volume of the inverse thermosensitive polymer between its transition temperature and physiological temperature is between about 80% and about 150% of the volume of the inverse thermosensitive polymer below its transition temperature.5. The method of claim 1 , wherein said inverse thermosensitive polymer is a block copolymer claim 1 , random copolymer claim 1 , graft polymer claim 1 , or branched copolymer.6. The method of claim 1 , wherein said inverse thermosensitive polymer is a block copolymer.7. The method of claim 1 , wherein said inverse thermosensitive polymer is a polyoxyalkylene block copolymer.8. The method of claim 1 , wherein said inverse thermosensitive polymer is a poloxamer or poloxamine.9. The method of claim 1 , wherein said inverse thermosensitive polymer is a poloxamer.10. The method of claim 1 , wherein said inverse thermosensitive ...

Подробнее
Номер записи: 33
14-01-2021 дата публикации

Adhesive Composition

Номер: US20210008244A1
Автор: Alexei Dmitrievitsj FILIPPOV, Marco DOMPÈ, Maria Magdalena Gerdina KAMPERMAN
Принадлежит: Rijksuniversiteit Groningen

The invention is directed to an adhesive complex coacervate composition, to a method of physically crosslinking an adhesive complex coacervate composition, to a method for adhering a tissue defect in a subject, and to the use of an adhesive complex coacervate composition. The adhesive complex coacervate composition of the invention comprises a polycation and a polyanion, wherein said polycation and polyanion together comprise on average at least two thermoresponsive moieties per polymer chain, said thermoresponsive moieties exhibiting a lower critical solution temperature, wherein said polycation comprises 5-70 mol % of thermoresponsive moieties and/or wherein said polyanion comprises 5-70 mol % of thermoresponsive moieties, and wherein said polycation and/or said polyanion is a graft or block copolymer comprising said thermoresponsive moieties.

Подробнее
Номер записи: 34
09-01-2020 дата публикации

LIQUID EMBOLIC AGENT COMPOSITION

Номер: US20200009290A1
Автор: NOMURA Takaomi, Ohkawa Kousaku, YUKI Ichiro
Принадлежит:

Provided is a liquid embolic agent composition capable of solving problems of conventional embolic agents, which can be used in a treatment of a vascular disease such as cerebral aneurysm. The problems are solved by a liquid embolic agent composition characterized in containing a hydrogel forming component having a calcium ion entrapping ability, and an anti-biodegradation component. The hydrogel forming component having a calcium ion entrapping ability is at least one kind of acidic polysaccharide selected from the group consisting of alginate, gellan gum, carrageenan, and carboxymethyl cellulose salt; and the anti-biodegradation component is at least one kind selected from the group consisting of hydroxypropyl methylcellulose, methylcellulose, polyvinyl alcohol, polyallylamine, poly-N-vinyl acetamide, and cellulose acetate. 19-. (canceled)10. A liquid embolic agent composition which comprises:a hydrogel forming component having a calcium ion entrapping ability; andan anti-biodegradable component,wherein the hydrogel forming component having a calcium ion entrapping ability comprises sodium alginate and gellan gum,wherein the anti-biodegradable component is hydroxypropyl cellulose, andwherein the liquid embolic agent composition is in a liquid state in vitro, and gelates by reacting with calcium ions in blood to exhibit a bioadhesiveness in vivo.11. The liquid embolic agent composition according to claim 10 , further comprising a coagulation promoting component claim 10 , wherein the coagulation promoting component is at least one selected from the group consisting of colloidal silica claim 10 , poly(N claim 10 ,N-dimethyl) acrylamide claim 10 , an enzyme preparation for food processing claim 10 , poly-L-lysine hydrobromide claim 10 , poly-L-glutamic acid sodium salt claim 10 , chitosan claim 10 , and silk fibroin.12. The liquid embolic agent composition according to claim 10 , which is used for treating cerebral aneurysm.13. The liquid embolic agent composition ...

Подробнее
Номер записи: 35
09-01-2020 дата публикации

METHODS AND COMPOSITIONS COMPRISING BIODEGRADABLE CYANOACRYLATES

Номер: US20200010728A1
Автор: LEE-SEPSICK Kathy
Принадлежит:

Disclosed herein are methods of making and using cyanoacrylate compositions comprising one or more cyanoacrylates, a high level of at least one stabilizing agent and at least one free-radical polymerization inhibitor. Methods disclosed comprise making such compositions and using such compositions, for example, for occluding conduits such as fallopian tubes. 1. A biodegradable cyanoacrylate composition , comprising ,a) a cyanoacrylate component comprising at least one cyanoacrylate, wherein the cyanoacrylate component is 80 wt % or greater;b) a stabilizer component in a range from 500 ppm to 1500 ppm; andc) a polymerization inhibitor component in a range from 4000 to 7000 ppm.2. The biodegradable cyanoacrylate composition of claim 1 , wherein the cyanoacrylate component comprises at least two cyanoacrylate monomers.3. The biodegradable cyanoacrylate composition of claim 1 , wherein the cyanoacrylate monomer is methyl cyanoacrylate claim 1 , ethyl cyanoacrylate claim 1 , propyl cyanoacrylate claim 1 , butyl cyanoacrylate claim 1 , pentyl cyanoacrylate claim 1 , hexyl cyanoacrylate claim 1 , septyl cyanoacrylate claim 1 , octyl nonyl cyanoacrylate claim 1 , decyl 2-cyanoacrylate claim 1 , allyl cyanoacrylate claim 1 , methoxyethyl cyanoacrylate claim 1 , methoxyisopropyl cyanoacrylate claim 1 , methoxypropyl cyanoacrylate claim 1 , methoxybutyl cyanoacrylate claim 1 , methoxypentyl cyanoacrylate claim 1 , or combinations thereof.4. The biodegradable cyanoacrylate composition of claim 1 , wherein the stabilizer component comprises an alkyl sulfide claim 1 , alkyl sulfate claim 1 , alkyl sulfonyl claim 1 , alkyl sulfone claim 1 , alkyl sulfoxide claim 1 , alkyl sulfite claim 1 , sultone claim 1 , sulfur dioxide claim 1 , sulfur trioxide claim 1 , sulfonic acid claim 1 , lactone claim 1 , boron trifluoride claim 1 , acetic acid claim 1 , or 3-sulfolene claim 1 , mercaptan claim 1 , or combinations thereof.5. The biodegradable cyanoacrylate composition of claim 4 , wherein ...

Подробнее
Номер записи: 36
03-02-2022 дата публикации

STABLE COMPOSITIONS COMPOSED OF A RADIOPAQUE AGENT AND CYANOACRYLATE MONOMER AND APPLICATIONS THEREOF

Номер: US20220031907A1
Автор: BASSAM Laura, BROADLEY Kenneth, Hynes Stephen, Kim David
Принадлежит:

Described herein are compositions composed of a radiopaque agent and a cyanoacrylate monomer. These compositions cure in situ when administered to a subject and, thus, have numerous biomedical applications. The presence of the radiopaque agent allows the practitioner to visualize the compositions during and immediately after administration to the subject. The compositions are non-toxic and shelf-stable, and can be sterilized to prevent microbial growth. The compositions can be pre-mixed prior to sale and distribution, reducing the need for special training in their use. 2. The composition of claim 1 , wherein the radiopaque agent comprises two groups comprising the structure I.4. The composition of claim 3 , wherein Rand Rare the same alkyl group.5. The composition of claim 4 , wherein Rand Rare each a Cto Calkyl group.6. The composition of claim 4 , wherein Rand Rare each methyl claim 4 , ethyl claim 4 , propyl claim 4 , butyl claim 4 , pentyl claim 4 , hexyl claim 4 , heptyl claim 4 , or octyl.7. The composition of claim 1 , wherein the cyanoacrylate monomer is an alkyl cyanoacrylate monomer claim 1 , a cycloalkyl cyanoacrylate monomer claim 1 , an allyl cyanoacrylate monomer claim 1 , an aryl cyanoacrylate monomer claim 1 , an aralkyl cyanoacrylate monomer claim 1 , a carboxy alkyl cyanoacrylate monomer or an iodo-substituted cyanoacrylate monomer.8. The composition of claim 1 , wherein the cyanoacrylate monomer is a C-Calkyl cyanoacrylate monomer.9. The composition of claim 1 , wherein the alkyl cyanoacrylate monomer is butyl cyanoacrylate monomer.10. The composition of claim 3 , wherein the cyanoacrylate monomer is butyl cyanoacrylate monomer and Rand Rare the same alkyl group.11. The composition of claim 10 , wherein Rand Rare each methyl claim 10 , ethyl claim 10 , propyl claim 10 , butyl claim 10 , pentyl claim 10 , heptyl claim 10 , or octyl.12. The composition of claim 1 , wherein the cyanoacrylate monomer is from 30 wt % to 90 wt % of the composition.13. ...

Подробнее
Номер записи: 37
19-01-2017 дата публикации

VACUUM MIXING SYSTEM AND METHOD FOR THE MIXING OF POLYMETHYLMETHACRYLATE BONE CEMENT

Номер: US20170014786A1
Автор: Kluge Thomas, VOGT Sebastian
Принадлежит: HERAEUS MEDICAL GMBH

Vacuum mixing systems and methods mix of polymethylmethacrylate bone cement, the systems and methods comprise at least one cartridge having an evacuable internal space, a pump with a plunger that can be moved by hand to generate a low pressure, and a connecting conduit connecting the internal space of the at least one cartridge to the pump. The pump comprises an operating element that can be operated from outside and is connected appropriately to the plunger such that it is suitable for moving the plunger in the pump by hand such that a low pressure can be generated such that the low pressure of the pump can be used to evacuate gas from the internal space of the at least one cartridge through the connecting conduit. 1. A vacuum mixing system for the mixing of polymethylmethacrylate bone cement , the system comprisingat least one cartridge having an evacuable internal space for mixing of the bone cement,a pump with a plunger movable by hand to generate a low pressure, anda connecting conduit connecting the internal space of the at least one cartridge to the pump,wherein the pump comprises an operating element operable from outside and connected appropriately to the plunger such that it is suitable for moving the plunger in the pump by hand such that a low pressure can be generated such that the low pressure of the pump is usable to evacuate gas from the internal space of the at least one cartridge through the connecting conduit,wherein a cement powder is contained in the cartridge and the vacuum mixing system comprising a container separate from the cartridge, the container containing a monomer liquid, wherein the container is connected via a liquid line to the cartridge, whereby the liquid conduit opens at the front side of the cartridge into the cartridge, and the connection conduit opens on the opposite rear side of the cartridge into the cartridge.2. The vacuum mixing system according to claim 1 , wherein the pump comprises a gas-tight pumping space on the inside ...

Подробнее
Номер записи: 38
21-01-2016 дата публикации

VACUUM MIXING SYSTEM AND METHOD FOR THE MIXING OF POLYMETHYLMETHACRYLATE BONE CEMENT

Номер: US20160015854A1
Автор: VOGT Sebastian
Принадлежит: HERAEUS MEDICAL GMBH

A vacuum mixing system for the mixing of polymethylmethacrylate bone cement comprising at least one cartridge () having an evacuatable internal space () for the mixing of the bone cement, the internal space () of which comprises a cylindrical swept volume, a mixing element () that is arranged in the internal space () of the cartridge () such as to be mobile and can be operated from outside the vacuum mixing system in order to mix the content in the internal space () of the cartridge (), and a dispensing plunger () having a cylindrical external circumference whose first base surface borders a base surface of the internal space () of the cartridge () and which can be or is locked to the cartridge () in detachable manner and which, in the detached state, is mobile in the cylindrical region of the internal space () of the cartridge (). 1. Vacuum mixing system for the mixing of polymethylmethacrylate bone cement , comprising{'b': 4', '104', '5', '105', '5', '105, 'at least one cartridge (, ) having an evacuatable internal space (, ) for the mixing of the bone cement, whereby the internal space (, ) comprises a cylindrical swept volume,'}{'b': 12', '112', '5', '105', '4', '104', '5', '105', '4', '104, 'a mixing element (, ) that is arranged in the internal space (, ) of the cartridge (, ) such as to be mobile and can be operated from outside the vacuum mixing system in order to mix the content in the internal space (, ) of the cartridge (, ), and'}{'b': 2', '102', '5', '105', '4', '104', '4', '104', '5', '105', '4', '104, 'a dispensing plunger (, ) having a cylindrical external circumference whose first base surface borders a base surface of the internal space (, ) of the cartridge (, ) and which can be or is locked to the cartridge (, ) in detachable manner and which, in the detached state, is mobile in the cylindrical region of the internal space (, ) of the cartridge (, ),'}{'b': 1', '101', '2', '102', '1', '101', '2', '102', '5', '105', '1', '101', '2', '102', '2', ' ...

Подробнее
Номер записи: 39
21-01-2016 дата публикации

SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS

Номер: US20160015855A1
Автор: Kobayashi Satoru, Matsuda Noriaki, Nohara Masahiro
Принадлежит: 3D-Matrix Ltd.

Compositions, methods and delivery devices (e.g., pre-filled syringes) for controlling bleeding during surgical procedures are provided, wherein the compositions are characterized as having an aqueous formulation that is capable of adopting a gelled state upon contact with bodily fluids and/or blood of a patient (i.e., physiological conditions).

Подробнее
Номер записи: 40
17-01-2019 дата публикации

EMBOLIC MICROSPHERES

Номер: US20190015545A1
Автор: Cao Hong, DeWitt Matthew R., FORSYTH BRUCE R., Schwanz Heidi, Zeng Hongxia
Принадлежит:

In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH-altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles. 1. Injectable particles comprising at least one pH-altering agent that is configured to be released from the injectable particles in vivo upon embolization of an intratumoral artery of a tumor with the injectable particles.2. The injectable particles of claim 1 , wherein the injectable particles are configured such that claim 1 , upon embolization of the intratumoral artery of the tumor with the injectable particles claim 1 , the injectable particles release the pH-altering agent such that a microenvironment is created in a vascular bed of the tumor downstream of the injectable particles that has a pH that is higher than a pH that would otherwise exist in the absence of the pH-altering agent.3. The injectable particles of claim 1 , wherein the injectable particles are spherical or non-spherical particles.4. The injectable particles of claim 1 , wherein the injectable particles range from 20 to 1500 microns in diameter.5. The injectable particles of claim 1 , wherein the pH-altering agent is (a) a basic agent having a pH value of 7.5 or more claim 1 , (b) a buffering agent having a pKa value of 7.6 or more claim 1 , or a combination of (a) and (b).6. The injectable particles of claim 1 , wherein the pH-altering agent is (a) a basic agent having a pH value ranging from 7.5 to 10 claim 1 , (b) a buffering agent having a pKa value ranging from 8 to 35 claim 1 , or (c) a combination of (a) and (b).7. The ...

Подробнее
Номер записи: 41
21-01-2021 дата публикации

RADIOPAQUE POLYMERS

Номер: US20210015963A1
Автор: Ashrafi Koorosh, Britton Hugh, Cuda Francesco, LEWIS Andrew Lennard, Parisi Cristian, TANG Yiqing, Willis Sean Leo
Принадлежит:

The present disclosure relates to radiopaque PVA polymers where the PVA has a first pendant group and a second pendant group, wherein the first pendant group comprises a first phenyl group bearing 1 to 5 iodine atoms, and the second pendant group comprises either (a) a second phenyl group bearing 1 to 3 substituents selected from the group W and optionally 1 to 4 iodine substituents, the group(s) W and the optional iodines being the sole substituents of the second phenyl group. Each W is selected from —OH, —COOH, —SOH, —OPOH, —O—(Calkyl), —O—(Calkyl)OH, —O—(Calkyl)R, —O—(CHO)R—(C═O)—O—Calkyl and —O—(C═O)Calkyl; wherein Ris H or Calkyl; Ris —COOH, —SOH, or —OPOH; q is an integer from 1 to 4; wherein the group W may be in the form of a pharmaceutically acceptable salt; or (b) a pyridyl group; which is optionally in the form of a pyridinium ion. 1. A polymer comprising polyvinyl alcohol (PVA) , the PVA having a first pendant group and a second pendant group ,wherein the first pendant group comprises a first phenyl group bearing 1 to 5 iodines as the sole substituent(s) of the first phenyl group, andwherein the second pendant group comprises a group selected from:(a) a second phenyl group bearing 1 to 3 substituents selected from the group W and optionally 1 to 4 iodine substituents, the group(s) W and the optional iodines being the sole substituents of the second phenyl group;{'sub': 3', '3', '2', '1-4', '1-4', '1-4', '2', '5', 'q', '1-4', '1-4', '1-4', '3', '3', '2, 'sup': 2', '1', '1', '2, 'wherein each W is independently selected from —OH, —COOH, —SOH, —OPOH, —O—(Calkyl), —O—(Calkyl)OH, —O—(Calkyl)R, —O—(CHO)R—(C═O)—O—Calkyl and —O—(C═O)Calkyl; wherein Ris H or Calkyl; Ris —COOH, —SOH, or —OPOH; wherein q is an integer from 1 to 4; and wherein the group W may be in the form of a pharmaceutically acceptable salt; and'}(b) a pyridyl group; which is optionally in the form of a pyridinium ion.2. A polymer according to claim 1 , wherein the first pendant group is coupled ...

Подробнее
Номер записи: 42
16-01-2020 дата публикации

Antimicrobial Adhesives Having Improved Properties

Номер: US20200016291A1
Автор: Wibaux Anne Marie
Принадлежит:

Adhesive compositions exhibiting antimicrobial properties, good stability, long shelf lives and enhanced release of antimicrobial agents are described. In certain versions, the compositions also exhibit relatively high fluid handling capacities. The adhesive compositions inhibit microbial growth by more than 2 log after 24 hours contact and particularly more than 3.5 log after 6 hours contact. Also described are various medical articles using such adhesives and related methods. 1. An antimicrobial adhesive composition comprising chlorhexidine and at least one non-gelling disintegrant;wherein the adhesive composition inhibits microbial growth by more than 2 log throughout a 7-day contact time period;wherein at least one non-gelling disintegrant is microcrystalline cellulose; andwherein the non-gelling disintegrant is 15% to 45% of the antimicrobial adhesive composition.2. The adhesive composition of wherein the adhesive composition exhibits a static absorption of at least about 5 g/m2/24 hours.3. The adhesive composition of wherein the adhesive composition also exhibits a moisture vapor transmission rate (MVTR) of at least 400 g/m2/24 hours.5. The medical article of wherein the adhesive composition exhibits a static absorption of at least about 5 g/m2/24 hours.6. The medical article of wherein the adhesive composition also exhibits a moisture vapor transmission rate (MVTR) of at least 400 g/m2/24 hours.8. The adhesive composition of wherein the adhesive composition is a pressure sensitive adhesive.9. The adhesive composition of wherein the adhesive component comprises an acrylic-based adhesive.10. The adhesive composition of wherein the adhesive component comprises a silicone-based adhesive.11. The adhesive composition of wherein the adhesive component comprises a rubber-based adhesive.12. The adhesive composition of wherein the adhesive component comprises a polyurethane-based adhesive.13. The adhesive composition of further comprising at least one agent selected ...

Подробнее
Номер записи: 43
25-01-2018 дата публикации

Manual mixer

Номер: US20180021744A1
Автор: Neil S. Sasaki
Принадлежит: Kyphon SARL

A manual mixer serves to facilitate mixing and agitating materials for use during surgery. For example, the manual mixer includes a body portion defining an interior area, a mixing assembly provided in the interior area of the body portion, a crank assembly for actuating the mixing assembly, and a valve assembly. The mixing assembly serves to mix and agitate the materials provided in the interior through rotation of a plunger portion and a spring attached thereto, and through upwards and downwards movement of the plunger portion in the interior area. Rotation of the crank assembly serves to rotate the plunger portion and the spring attached thereto, and effectuate upwards and downwards movement of the plunger portion. The valve assembly can be opened to facilitate dispensing of the materials from the interior area.

Подробнее
Номер записи: 44
17-04-2014 дата публикации

Polymeric treatment compositions

Номер: US20140107251A1
Автор: Clayton Harris, Edward Michael Keeley, Gregory M. Cruise, Michael J. Constant, Rob GREENE
Принадлежит: MicroVention Inc

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological pH solution; wherein the biocompatible polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

Подробнее
Номер записи: 45
10-02-2022 дата публикации

ROLL PRODUCT WITH CUT LINES

Номер: US20220041894A1
Автор: Kinoshita Yasuhiro, MATSUKI KOSUKE, SATO FUMISHI
Принадлежит: 3M INNOVATIVE PROPERTIES COMPANY

The roll product includes an arrangement of actual cut lines to improve hand-tearability and strength. Between the actual cut lines are virtual cut lines. A set of actual cut lines and virtual cut lines forms a cutting induction portion. A plurality of rows of virtual cut lines are arranged in a width direction in each of the cutting induction portions and are formed in a longitudinal direction of the roll product. 16-. (canceled)7. A roll product comprising a band-shaped member having longitudinal direction and width direction , wherein the band-shaped member is wound in a roll shape along the longitudinal direction , the roll product comprises:a plurality of cutting induction portions extending in a width direction of the band-shaped member are formed in the band-shaped member in a longitudinal direction of the band-shaped member; a plurality of actual cut lines arranged to be spaced apart from each other in the width direction, and formed by partially cutting the base member, and', 'a plurality of virtual cut lines set by connecting ends of the plurality of actual cut lines;, 'each of the plurality of cutting induction portions comprisesthe plurality of virtual cut lines include a virtual cut line extending from a first end of a first actual cut line of the plurality of actual cut lines and connected to one of ends of a second actual cut line different from the first actual cut line, and the one of the ends of the second actual cut line is closest to the first end of the ends of the second actual cut line;the plurality of virtual cut lines include a virtual cut line extending from a second end of the first actual cut line and connected to one of ends of a third actual cut line different from the first actual cut line and the second actual cut line, and the one of the ends of the third actual cut line is closest to the second end of the ends of the third actual cut line;a plurality of rows of the virtual cut lines arranged in the width direction are formed in the ...

Подробнее
Номер записи: 46
23-01-2020 дата публикации

ADHESIVE FOR HARD TISSUE BONDING, ADHESIVE KIT FOR HARD TISSUE BONDING, AND BONE CEMENT

Номер: US20200023095A1
Автор: Aida Syuhei, Fukuyama Shigeo, HASHIMOTO Kazuaki, Meguro Takashi, Shibata Hirobumi, Tanaka Shinya
Принадлежит:

An adhesive for hard tissue bonding which has a sufficient pot life and excellent biocompatibility and is replaced with bone over time, and an adhesive kit for hard tissue bonding are provided. In addition, bone cement is provided which has excellent biocompatibility and is replaced with bone over time. An adhesive for hard tissue bonding includes: a cyanoacrylate monomer; and beta-tricalcium phosphate or hydroxyapatite. An adhesive kit for hard tissue bonding includes: a liquid agent containing a cyanoacrylate monomer; and a powdery agent containing beta-tricalcium phosphate or hydroxyapatite. Bone cement includes: a cyanoacrylate polymer; and beta-tricalcium phosphate or hydroxyapatite. 1. An adhesive for hard tissue bonding , the adhesive comprising:a cyanoacrylate monomer, andbeta-tricalcium phosphate or hydroxyapatite.2. The adhesive for hard tissue bonding according to claim 1 ,wherein in the beta-tricalcium phosphate, a part of a calcium position in a crystal is replaced with a magnesium ion by dissolution and some vacancies existing in a crystalline structure are replaced with sodium ions by dissolution.3. The adhesive for hard tissue bonding according to claim 1 ,wherein in the beta-tricalcium phosphate, a part of a phosphorus position in a crystal is replaced with a silicon ion by dissolution.4. The adhesive for hard tissue bonding according to claim 3 , the adhesive further comprising:less than or equal to 5 mol % of the silicon ions with respect to all anion positions.5. The adhesive for hard tissue bonding according to claim 1 ,wherein an average particle diameter of the beta-tricalcium phosphate and the hydroxyapatite is less than or equal to 100 μm.6. The adhesive for hard tissue bonding according to claim 1 ,wherein an average particle diameter of the beta-tricalcium phosphate and the hydroxyapatite is less than or equal to 50 μm.7. The adhesive for hard tissue bonding according to claim 1 ,wherein the beta-tricalcium phosphate and the hydroxyapatite ...

Подробнее
Номер записи: 47
28-01-2021 дата публикации

Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods ofpreparing and using the same

Номер: US20210023015A1
Автор: Alexander Kuller, Jaques BLUMMEL, Olaf Fritz, Ronald Wojcik, Thomas A. Gordy, Ulf Fritz
Принадлежит: Boston Scientific Ltd Barbados, Celanova Biosciences Inc, Varian Medical Systems Inc

Polymeric particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene and/or a derivative thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in specific selected sizes to allow for selective embolization of certain sized blood vessels or localized treatment with an active component agent in specific clinical uses. Particles of the present invention may further be provided as color-coded microspheres or nanospheres to allow ready identification of the sized particles in use. Such color-coded microspheres or nanospheres may further be provided in like color-coded delivery or containment devices to enhance user identification and provide visual confirmation of the use of a specifically desired size of microspheres or nanospheres.

Подробнее
Номер записи: 48
28-01-2021 дата публикации

POLY (IONIC LIQUID) COMPOSITIONS AND THEIR USE AS TISSUE ADHESIVES

Номер: US20210023259A1
Автор: NOSHADI Iman
Принадлежит:

The present invention relates to the discovery of methods of treating a wound in a subject in need thereof. In certain embodiments, the method comprises contacting the wound with a composition comprising gelatin methacrylate and choline acrylate, and then polymerizing the composition to form a polymerized composition having a plurality of choline acrylate functionalized gelatin methacrylate units. 1. A method of treating a wound in a subject in need thereof , the method comprising:(a) contacting the wound with a composition comprising:a polymer selected from the group consisting of gelatin methacrylate (GelMa) and poly(ethylene glycol) diacrylate (PEGDA);choline acrylate; andat least one photoinitiator; and(b) exposing the composition to at least one wavelength of light capable of activating the at least one photoinitiator, thereby polymerizing the composition.2. The method of claim 1 , wherein the composition comprises about 1:4 to about 4:1 choline acrylate to polymer.3. (canceled)4. The method of claim 1 , wherein at least one photoinitiator is selected from the group consisting of eosin Y claim 1 , 2-hydroxy-2-methylpropiophenone claim 1 , 2-methyl-4′-(methylthio)-2-morpholinopropiophenone claim 1 , lithium phenyl-2 claim 1 ,4 claim 1 ,6-trimethylbenzoylphosphinate (LAP) claim 1 , and 2-hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone (Irgacure).5. The method of claim 1 , wherein the composition further comprises at least one additional compound selected from the group consisting of triethanolamine (TEOA) and N-vinylcaprolactam (VC).6. (canceled)7. The method of claim 1 , wherein the composition comprises about 10% to about 20% (w/v) choline acrylate.8. The method of claim 1 , wherein the composition comprises about 10% to about 30% (w/v) polymer.9. The method of claim 4 , wherein the composition comprises at least one of:about 0.1 mM eosin Y;0.5% (w/v) LAP;about 1.5% (w/v) TEOA; orabout 1% (w/v) VC.10. (canceled)11. (canceled)12. (canceled)13. The method of ...

Подробнее
Номер записи: 49
28-01-2021 дата публикации

COMPOSITION FOR HARD TISSUE REPAIR AND KIT FOR HARD TISSUE REPAIR

Номер: US20210023260A1
Автор: Aoki Shinya, BANDO Ayako, Goto Kengo, Miura Takashi, Nakagawa Aya, Yang Jingjing
Принадлежит: Mitsui Chemicals, Inc.

The application discloses a composition for hard tissue repair comprising a monomer (A), a polymer powder (B) and a polymerization initiator (C), wherein the polymer powder (B) comprises a polymer powder (B-x) having an aspect ratio of 1.10 or more, and the cumulative ratio of powder particles having aspect ratios of 1.00 or more and less than 1.10 in all of the powder particles contained in the composition for hard tissue repair is 75 cumulative % or less, as well as, a kit for hard tissue repair comprising three or more members, in which each of the components of the monomer (A), the polymer powder (B) and the polymerization initiator (C) contained in this composition for hard tissue repair are divided and contained in the members in an optional combination. 1. A composition for hard tissue repair comprising a monomer (A) , a polymer powder (B) and a polymerization initiator (C) , whereinthe polymer powder (B) comprises a polymer powder (B-x) having an aspect ratio of 1.10 or more, andthe cumulative ratio of powder particles having aspect ratios of 1.00 or more and less than 1.10 in all of the powder particles contained in the composition for hard tissue repair is 75 cumulative % or less.2. The composition for hard tissue repair according to claim 1 , wherein the cumulative ratio of powder particles having aspect ratios of 1.00 or more and less than 1.10 in all of the powder particles contained in the composition for hard tissue repair is 2.5 cumulative % or more claim 1 , and 65 cumulative % or less.3. The composition for hard tissue repair according to claim 1 , wherein the polymer powder (B) comprises a polymer powder (B-x) having an aspect ratio of 1.10 or more and 1.90 or less claim 1 , and the aspect ratio of all of the polymer powder (B) is 1.11 or more and 1.80 or less.4. The composition for hard tissue repair according to claim 1 , wherein the monomer (A) is a (meth)acrylate-based monomer.5. The composition for hard tissue repair according to claim 1 , ...

Подробнее
Номер записи: 50
28-01-2021 дата публикации

POLYMERIC TREATMENT COMPOSITIONS

Номер: US20210023261A1
Автор: Constant Michael J., Cruise Gregory M., Greene Rob, Harris Clayton, Keeley Edward Michael
Принадлежит:

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological solution; wherein the biocompatible polymer is soluble in the non-physiological solution and insoluble in a physiological solution. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use. 1. A polymeric composition comprising: 'a first monomer including a biodegradable linkage to a visualization agent, and a second monomer including at least one hydroxyl group; and', 'a substantially stable biocompatible polymer comprising a reaction product ofwherein the substantially stable biocompatible polymer is dissolved in a solution.2. The polymeric composition of claim 1 , wherein the visualization agent includes at least one aromatic ring.3. The polymeric composition of claim 2 , wherein the at least one aromatic ring at least one iodine atom.4. The polymeric composition of claim 1 , wherein the solution is a non-physiological solution.5. The polymeric composition of claim 4 , wherein the non-physiological solution is a water miscible solvent.6. The polymeric composition of claim 5 , wherein the concentration of the substantially stable biocompatible polymer in the water miscible solvent is about 1% to about 50%.7. The polymeric composition of claim 1 , wherein the second monomer is hydroxyethyl methacrylate.8. The polymeric composition of claim 1 , wherein the biodegradable linkage is Seq. ID 1 claim 1 , Seq. ID 2 claim 1 , Seq. ID 3 claim 1 , Seq. ID 4 claim 1 , Seq. ID 5 claim 1 , Seq. ID 6 claim 1 , Seq. ID 7 claim 1 , Seq. ID 8 claim 1 , Seq. ID 9 claim 1 , Seq. ID 10 claim 1 , Seq. ID 11 claim 1 , or Seq. ID 12.9. The polymeric composition of claim 1 , wherein the biodegradable linkage is an ester or a polyester.10. The polymeric composition of claim 1 , wherein the substantially stable biocompatible polymer is a reaction product of 2-oxo-2-(1-oxo-1-(1-oxo-1-(2 claim 1 ,4 ...

Подробнее
Номер записи: 51
02-02-2017 дата публикации

METHOD FOR THE PRODUCTION OF POLY(2-OCTYL CYANOACRYLATE)-POLYISOBUTYLENE CO-NETWORK, AND SUPER INITIATORS THEREFOR

Номер: US20170028099A1
Автор: Kennedy Joseph, Szanka Amalia, Szanka Istvan
Принадлежит: THE UNIVERSITY OF AKRON

A method for increasing the rate of polymerization of 2-octyl cyanoacrylate, or the rate of copolymerization of 2-octyl cyanoacrylate and a tri-telechelic star polymer comprising polyisobutylene terminated with cyanoacrylate groups (Ø(PIB-CA)) to form a co-network, is provided. The method comprise initiating the polymerization of 2-octyl cyanoacrylate, or the copolymerization of 2-octyl cyanoacrylate and a tri-telechelic star polymer comprising polyisobutylene terminated with cyanoacrylate groups (Ø(PIB-CA)) to form the co-network, with an initiator selected from the group consisting of cyclic tertiary aliphatic amines optionally dissolved in a non-aqueous solvent. The cyclic tertiary aliphatic amines are selected from the group consisting of azabicyclo[2.2.2]-octane (ABCO), and 1,4-diazabicyclo[2.2.2]-octane (DABCO). 1. A method for increasing the rate of polymerization of 2-octyl cyanoacrylate , or the rate of copolymerization of 2-octyl cyanoacrylate and a tri-telechelic star polymer comprising polyisobutylene terminated with cyanoacrylate groups (Ø(PIB-CA) ,) to form a co-network , the method comprising:{'sub': '3', 'initiating the polymerization of 2-octyl cyanoacrylate, or the copolymerization of 2-octyl cyanoacrylate and Ø(PIB-CA)to form the co-network, with an initiator selected from the group consisting of cyclic tertiary aliphatic amines optionally dissolved in a non-aqueous solvent.'}2. The method according to claim 1 , wherein the cyclic tertiary aliphatic amines are selected from the group consisting of azabicyclo[2.2.2]-octane (ABCO) claim 1 , and 1 claim 1 ,4-diazabicyclo[2.2.2]-octane (DABCO).3. The method according to claim 1 , wherein the non-aqueous solvent is used and is selected from the group consisting of tetrahydrofuran (THF) claim 1 , toluene claim 1 , and combinations thereof.4. The method according to claim 1 , wherein the step of initiating further includes further initiating the polymerization or copolymerization with nucleophilic groups ...

Подробнее
Номер записи: 52
04-02-2016 дата публикации

TREATMENT FOR BILE LEAKAGE

Номер: US20160030628A1
Автор: Kobayashi Satoru
Принадлежит: 3-D Matrix, Ltd.

Materials and methods for treating bile leakage are disclosed. A peptide comprising between about 7 amino acids to about 32 amino acids may be introduced to a target site. The peptide may undergo self-assembly upon adjustment of a pH level of the solution to a physiological pH level. 1. A method of treating a bile leakage in a subject comprising:positioning an end of a delivery device in a target area of the bile leakage in which an occlusion is desired;administering through the delivery device a solution comprising a self-assembling peptide comprising between about 7 amino acids and about 32 amino acids in an effective amount and in an effective concentration to form a hydrogel under conditions surrounding the bile leakage to provide an occlusion of the bile leakage;removing the delivery device from the target area of the bile leakage.2. The method of claim 1 , further comprising visualizing a region comprising at least a portion of the target area surrounding the bile leakage.3. The method of claim 2 , wherein visualizing the region comprises visualizing the region during at least one of:identifying the target area of the bile leakage;positioning the end of the delivery device in the target area;administering the solution;removing the delivery device; andmonitoring the bile leakage after removing the delivery device.4. The method of claim 3 , wherein visualizing the region provides for selective administration of the solution to the target area of the bile leakage.5. The method of claim 3 , further comprising visualizing the region in a time period of about one minute subsequent to administering the solution.6. The method of claim 5 , further comprising visualizing the region in a time period of about three minutes subsequent to administering the solution.7. The method of claim 6 , further comprising visualizing the region in a time period of about one week subsequent to administering the solution.8. The method of claim 1 , wherein at least one of the effective ...

Подробнее
Номер записи: 53
30-01-2020 дата публикации

Microspheres containing therapeutic agents and related methods of use

Номер: US20200030238A1
Автор: Philippe Reb
Принадлежит: Biosphere Medical Inc

Microspheres, compositions including the microspheres, and methods of using the microspheres are disclosed herein. The microspheres can be substantially spherical and can include a copolymer of a monomer (such as an acrylic monomer) and a cyclodextrin or a derivative thereof. The microspheres can also include a therapeutic agent, such as a platinum-based drug.

Подробнее
Номер записи: 54
30-01-2020 дата публикации

COMPOSITION FOR HARD TISSUE REPAIR AND KIT FOR HARD TISSUE REPAIR

Номер: US20200030484A1
Автор: Aoki Shinya, BANDO Ayako, Goto Kengo, Hamada Tetsuya, Miura Takashi
Принадлежит: Mitsui Chemicals, Inc.

Disclosed are: a composition for hard tissue repair with excellent penetrability to an adherend such as a cancellous bone and excellent adhesion to an adherend, which comprises a monomer (A), a polymer powder (B) comprising 54% by mass or more of a polymer powder (b1) having a volume mean particle diameter of 27 to 80 μm and a polymerization initiator (C); and a kit for hard tissue repair comprising members in which the components of the monomer (A), the polymer powder (B) and the polymerization initiator (C) contained in this composition for hard tissue repair are encased in three or more divided groups in an optional combination. 1. A composition for hard tissue repair comprising a monomer (A) , a polymer powder (B) comprising 54% by mass or more of a polymer powder (b1) having a volume mean particle diameter of 27 to 80 μm and a polymerization initiator (C).2. The composition for hard tissue repair according to claim 1 , wherein the simulated bone penetrability as measured by the following method is 1.0 mm or more: [method of measuring simulated bone penetrability]A simulated bone penetrability is measured by impregnating a polyurethane foam having open cell porous (porosity 95%) with physiological saline, putting the composition on the polyurethane impregnated with the physiological saline at 5 minutes after the composition becomes a soft mass and has no more stringiness, applying a pressure load of 75 kPa for 30 seconds to the composition on the polyurethane, measuring the penetration depth (mm) of the composition into the polyurethane foam.3. The composition for hard tissue repair according to claim 1 , further comprising a contrast medium (X) having a volume mean particle diameter of less than 3.0 μm.4. The composition for hard tissue repair according to claim 1 , wherein the monomer (A) is a (meth)acrylate-based monomer.5. The composition for hard tissue repair according to claim 1 , wherein the polymer powder (B) is a (meth)acrylate-based polymer powder.6. ...

Подробнее
Номер записи: 55
30-01-2020 дата публикации

COMPOSITION FOR HARD TISSUE REPAIR AND KIT FOR HARD TISSUE REPAIR

Номер: US20200030485A1
Автор: Aoki Shinya, BANDO Ayako, Goto Kengo, Hamada Tetsuya, Miura Takashi
Принадлежит: Mitsui Chemicals, Inc.

Disclosed are: a composition for hard tissue repair with excellent penetrability to an adherend such as a cancellous bone and excellent adhesion to an adherend, which comprises a monomer (A), a polymer (B), a polymerization initiator (C) and a contrast medium (X) having a volume mean particle diameter of 3 μm or more; and a kit for hard tissue repair having members in which the components of the monomer (A), the polymer (B), the polymerization initiator (C) and the contrast medium (X) contained in this composition for hard tissue repair are encased in three or more divided groups in an optional combination. 1. A composition for hard tissue repair comprising a monomer (A) , a polymer (B) , a polymerization initiator (C) and a contrast medium (X) having a volume mean particle diameter of 3 μm or more.3. The composition for hard tissue repair according to claim 1 , wherein the contrast medium (X) is barium sulfate or zirconia.4. The composition for hard tissue repair according to claim 1 , wherein the monomer (A) is a (meth)acrylate type monomer.5. The composition for hard tissue repair according to claim 1 , wherein the polymer (B) is a (meth)acrylate-based polymer.6. The composition for hard tissue repair according to claim 1 , comprising 10 to 45 parts by mass of the monomer (A) claim 1 , 54.9 to 80 parts by mass of the polymer (B) and 0.1 to 10 parts by mass of the polymerization initiator (C) (the sum of the components (A) to (C) is taken as 100 parts by mass) claim 1 , and 0.5 to 70 parts by mass of the contrast medium (X).7. The composition for hard tissue repair according to claim 1 , wherein the volume mean particle diameter of the contrast medium (X) is 3.0 to 25.1 μm.8. The composition for hard tissue repair according to claim 1 , wherein the volume mean particle diameter of all particles contained in the composition for hard tissue repair is 32 μm or less.9. A kit for hard tissue repair comprising three or more members claim 1 , in which each of the ...

Подробнее
Номер записи: 56
31-01-2019 дата публикации

POLYMER PARTICLES

Номер: US20190031798A1
Автор: Cruise Gregory M., Harris Clayton, Keeley Edward Michael, Plotkin Steve, Yu Renee
Принадлежит:

Polymer particle embolics and methods of making same are described. The particle embolics can be used as embolization agents. 1. A polymer particle comprising:poly(ethylene glycol) diacrylamide, glycerol monomethacrylate, and amino ethyl methacrylate;wherein the polymer particle is spherical and has a diameter less than about 1,200 μm.2. The polymer particle of , wherein the polymer particle has a diameter between about 40 μm and about 1 ,200 μm. The polymer particle of , further comprising N ,N-methylenebisacrylamide.4. The polymer particle of claim 1 , wherein the N claim 1 ,N-methylenebisacrylamide is at a concentration of about 1% w/w.5. The polymer particle of claim 1 , wherein the poly(ethylene glycol) diacrylamide is at a concentration of about 28% w/w.6. The polymer particle of claim 1 , wherein the glycerol monomethacrylate is present at a concentration of about 68% w/w claim 1 ,7. The polymer particle of claim 1 , wherein the amino ethyl methacrylate at a concentration of about 3% w/w.8. The polymer particle of claim 1 , wherein the poly(ethylene glycol) diacrylamide is poly(ethylene glycol) diacrylamide 10 claim 1 ,000.9. The particle of claim 1 , further comprising a drug.10. A polymer particle comprising:poly(ethylene glycol) diacrylamide, 3-sulfopropyl acrylate, and amino propyl methacrylamide,wherein the polymer particle is spherical and has a diameter less than about 1,200 μm.11. The polymer particle of claim 10 , wherein the polymer particle has a diameter between about 40 pm and about 1 claim 10 ,200 μm.12. The polymer particle of claim 10 , wherein the poly(ethylene glycol) diacrylamide is at a concentration of about 40% w/w.13. The polymer particle of claim 10 , wherein the at least one monomer is 3-sulfopropyl acrylate at a concentration of about 59% w/w.14. The polymer particle of claim 10 , wherein the amino propyl methacrylamide is at a concentration of about 1% w/w.15. The polymer particle of claim 10 , wherein the poly(ethylene glycol) ...

Подробнее
Номер записи: 57
11-02-2016 дата публикации

COMPOSITIONS HAVING CYLINDRICAL VOLUME, METHODS, AND APPLICATORS FOR SEALING INJURIES

Номер: US20160038347A1
Автор: BEALL Dawson, BRICHETTI Jennifer, MACPHEE Martin, WILMER Belinda
Принадлежит:

Disclosed are solid and frozen haemostatic materials having a rod shape and suitable applicators and plungers for application of such dressings to wounded tissue wherein said dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings, particularly for the treatment of injured tissue via endoscopic or minimally-invasive surgical techniques. 1. A haemostatic material for treating wounded internal tissue in a mammal comprising a cylindrical haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator wherein said cylindrical haemostaic material is made by combining liquid fibrinogen and liquid fibrinogen at about 12° C. to 0° C. and preferable between 4° C.+/−2° C. into a cylindrical mold , freezing and thereafter lyophilizing said material , wherein said fibrinogen component is present in an amount between 1 mg/cmand 75 mg/cmand said fibrinogen activator is present in an amount between about 0.01 to about 1.0 U/mg fibrinogen component; wherein said liquid combination is thereafter frozen and lyophilized.2. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one cylindrical haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to reduce the flow of fluid from said wounded tissue and/or join or approximate said wounded tissue , wherein said haemostatic material is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator , wherein said fibrinogen component is present in an amount between 1 mg/ml and 37.5 mg/ml and said fibrinogen activator is present in an amount between about 0.01 to about 1.0 U/mg fibrinogen component; wherein said liquid combination is thereafter frozen and lyophilized. ...

Подробнее
Номер записи: 58
11-02-2016 дата публикации

Adhesive Properties

Номер: US20160038629A1
Автор: Neal CARTY
Принадлежит: Avery Dennison Corp

Various adhesive compositions are described which may optionally comprise one or more active agents such as pharmaceutical agents. The incorporation of one or more absorbents in combination with one or more crystallization inhibitors improves adhesive characteristics of the compositions. Also described are related methods of improving adhesive characteristics of adhesive compositions with the use of a combination of absorbent and inhibitor. Also described are related methods of using the compositions and articles incorporating such compositions.

Подробнее
Номер записи: 59
11-02-2016 дата публикации

MALLEABLE, BIODEGRADABLE HEMOSTATIC AGENT

Номер: US20160038630A1
Автор: VOGT Sebastian
Принадлежит:

A malleable, biodegradable hemostatic agent is provided that can be used for mechanical sealing of bleeding bone tissue, as well as a method for forming a malleable, biodegradable hemostatic agent of this type, and a medical implant having a coating that includes a malleable, biodegradable hemostatic agent of this type. The malleable, biodegradable hemostatic agent contains (a) at least one saturated glycerol-1,2,3-tri-fatty acid ester having a melting temperature above 37° C., (b) at least one filling agent present in particulate form, at least in part, and having a melting temperature above 37° C., and (c) at least one compound having a melting temperature not above 37° C. and a solubility at a temperature of 25° C. of less than 50 grams per liter of water. 1. A malleable , biodegradable hemostatic agent comprising a malleable , biodegradable composition having hemostatic properties , the composition containing a mixture of the following components:(a) at least one saturated glycerol-1,2,3-tri-fatty acid ester having a melting temperature above 37° C.;(b) at least one filling agent at least partially present in particulate form and having a melting temperature above 37° C., wherein component (b) has a solubility at a temperature of 25° C. of at least 100 grams per liter of water and is selected from the group consisting of polymers of at least one alkylene oxide and copolymers of at least one alkylene oxide; and(c) at least one compound having a melting temperature not above 37° C. and a solubility at a temperature of 25° C. of less than 50 grams per liter of water, wherein component (c) is a saturated fatty acid ester.2. The malleable claim 1 , biodegradable hemostatic agent according to claim 1 , wherein the hemostatic agent has a pH in water at a temperature of 25° C. in a range of 5.0-9.0.3. The malleable claim 1 , biodegradable hemostatic agent according to claim 1 , wherein the hemostatic agent has a pH in water at a temperature of 25° C. in a range of 5.5-8 ...

Подробнее
Номер записи: 60
11-02-2016 дата публикации

Acrylic Cements for Bone Augmentation

Номер: US20160038631A1
Автор: Alejandroö LOPEZ, Cecilia PERSSON
Принадлежит: Inossia Ab

The embodiments relate to an injectable composition for a bone cement material comprising a dry powder component, a liquid component and a modifier configured to modify a Young's modulus of the bone cement material. The modifier is linoleic acid or a derivative thereof and is present in a concentration of 0.1 to 12 v/v of the liquid component.

Подробнее
Номер записи: 61
05-02-2015 дата публикации

Systems, Devices, Components and Methods for Improved Acoustic Coupling Between a Bone Conduction Hearing Device and a Patient's Head or Skull

Номер: US20150038775A1
Автор: Ruppersberg Peter
Принадлежит: SOPHONO, INC.

Disclosed are various embodiments of systems, devices, components and methods for improving acoustic coupling between a bone conduction hearing device (BCHD) and a patient's head or skull. Such systems, devices, components and methods include disposing a gel or paste between the BCHD and the patient's skin, hair and/or skull. The gel or paste improves the transmission of acoustic signals generated by a transducer in the BCHD to the patients head or skull by providing a more efficient and improved intermediary acoustic medium for the transmission of acoustic signals to the patient's head or skull. 1. A method of improving acoustic coupling between a bone conduction hearing device (BCHD and a patient's head or skull , the BCHD comprising a transducer configured to generate sound signals for transmission to the patient's skull , the method comprising:applying an aqueous gel or paste to a bottom surface of the BCHD, andattaching, securing or magnetically coupling the BCHD to or against the patient's head or skull;wherein at least portions of the gel or paste are operably disposed between the bottom surface of the BCHD and the patient's head or skull thereby to improve acoustic coupling and transmission of the sound signals generated the transducer to the patient's skull.2. The method of claim 1 , wherein a baseplate or spacer is operably connected to or forms a portion of the BCHD and is operably attached to or forms a portion of the transducer.3. The method of claim 1 , wherein the transducer is an electromagnetic (“EM”) transducer or a piezoelectric transducer.4. The method of claim 1 , wherein the BCHD is a magnetic BCHD.5. The method of claim 4 , wherein a magnetic implant is attached to or in the patient's skull beneath the patient's skin at an implant location claim 4 , and is configured to magnetically couple to the magnetic BCHD.6. The method of claim 5 , wherein the magnetic BCHD is magnetically attached to the patient's skull over the implant location.7. The ...

Подробнее
Номер записи: 62
04-02-2021 дата публикации

ADHESIVE BONDING COMPOSITION AND ELECTRONIC COMPONENTS PREPARED FROM THE SAME

Номер: US20210035946A1
Автор: Bourke, Clayton James, Fathi Zakaryae, JR. Frederic A., Walder Harold
Принадлежит: Immunolight, LLC

A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like. 1. (canceled)2. An anisotropic conductive polymer sphere comprising a polymeric core having at least a portion of an outer surface of the sphere coated with at least one down-converting material that responds to X-ray photons.3. The anisotropic conductive polymer sphere of claim 2 , further comprising an outer coating of silica.4. The anisotropic conductive polymer sphere of claim 2 , wherein the at least one down-converting material is in a form of nanoparticles.5. An anisotropic conductive polymer sphere comprising a polymeric core having at least a portion of an outer surface of the sphere coated with at least one up-converting material that responds to near infrared photons.6. The anisotropic conductive polymer sphere of claim 5 , further comprising an outer coating of silica.7. The anisotropic conductive polymer sphere of claim 5 , wherein the at least one up-converting material is in a form of nanoparticles.8. An X-ray unit that simultaneously causes down-converting particles of ACA spheres to radiate at a selected ...

Подробнее
Номер записи: 63
07-02-2019 дата публикации

CURABLE POLYMERIC MATERIALS AND METHODS OF USING SAME

Номер: US20190038799A1
Автор: Beveridge Nicole Morozowich, Demirgöz Döne, DiZio James P., Griesgraber George W., Kipke Cary A., Klein Andrew P., Rasmussen Jerald K., Touris Athanasios
Принадлежит:

Polymeric materials are disclosed herein that include a Polymer A, a Polymer B, and an oxalate ester or reaction product thereof. Polymer A contains electrophilic reactive groups, and Polymer B contains nucleophilic groups. In certain embodiments, the polymeric materials are free-flowing liquids at 100% solids that can be used, for example, as topical skin adhesives. 2. The two-part reactive composition of claim 1 , wherein Polymer A comprises a range of 25 to 93 weight percent of the monomeric units of Formula (I).3. The two-part reactive composition of claim 1 , wherein Polymer A further comprises a monomeric unit comprising a siloxane group.4. The two-part reactive composition of claim 1 , wherein Polymer A further comprises a monomeric unit formed from a monomer comprising an acidic group selected from the group consisting of acrylic acid claim 1 , 2-carboxyethyl acrylate claim 1 , 2-carboxyethyl acrylate oligomers claim 1 , and combinations thereof.5. The two-part reactive composition of claim 1 , wherein Polymer A further comprises a monomeric unit comprising a plurality of (meth)acryloyl groups.6. The two-part reactive composition of claim 1 , wherein Polymer A has a weight average molecular weight (M) in a range of 10 claim 1 ,000 Daltons to 100 claim 1 ,000 Daltons.7. The two-part reactive composition of claim 6 , wherein the first part further comprises an oligomeric or polymeric additive.8. The two-part reactive composition of claim 7 , wherein the oligomeric or polymeric additive has a weight average molecular weight (M) of less than 10 claim 7 ,000 Daltons.10. The two-part reactive composition of claim 1 , wherein Polymer B has a weight average molecular weight (M) of at least 12 claim 1 ,000 Daltons and a weight average molecular weight (M) of no greater than 100 claim 1 ,000 Daltons.11. The two-part reactive composition of claim 1 , wherein a monomeric unit of the plurality of monomeric units of Polymer B having a primary amino group is a reaction ...

Подробнее
Номер записи: 64
12-02-2015 дата публикации

Co-precipitation method

Номер: US20150045455A1
Автор: Charles Vaughn Cassingham, Jon Mckannan, Tina Lanette MCARTHUR, Tracy Hutchison
Принадлежит: NeoMend Inc

Methods for preparing a PEG composition by co-precipitation of two or more components to produce a substantially homogenous powder. According to some embodiments, the two or more components are at least and partially soluble in a solvent, and at least one component is a functionalized PEG. Contacting the at least two component with the solvent at least partially dissolves the components which are then co-precipitated. The resulting product is substantially homogenous, unlike product made by other methods. The PEG composition may be co-precipitated with additional compounds, such as a colorant like indocyanine green.

Подробнее
Номер записи: 65
15-02-2018 дата публикации

METHOD AND APPARATUS TO CONTROL THE HETEROGENEOUS FLOW OF BONE CEMENT AND IMPROVE OSSEOINTEGRATION OF CEMENTED IMPLANT

Номер: US20180043053A1
Автор: KHANDAKER Morshed, RIAHINEZHAD Shahram
Принадлежит:

The present invention provides processes for combined applications of making grooves on an implant surface, applying MgO nanoparticles with PMMA cement, restricting the cement movement by PCL nanofiber and tethering biomolecules with PCL nanofiber to enhance mechanical stability and osseointegration of PMMA cement with bone. This is achieved through enhanced osteoconductive properties, roughness, and less viable fracture originating sites at the bone-cement interface. Such combined applications of nanoparticle and nanofiber on the mechanical stability and osseointegration of cemented implant is heretofore unknown, but as provided by the present invention can solve the debonding problem of cemented implant from bone. 1. A process providing a method to enhance mechanical stability and osseointegration of PolyMethylMethAcrylate (PMMA) cement with bone in surgeries using a metallic implant , comprising:amending surface areas of said implant using at least one of grooves or ion deposition;mixing nanoparticles as additives with PMMA cement;immobilizing osteoconductive nanomaterials with electrospun nanofibers (ENF), andconstruction of a membrane using said ENF said membrane exhibiting adequate stiffness to control the movement of said cement into said bone,wherein said nanofiber membrane is inserted into a formed cavity in said bone, said PMMA cement is deposited into said nanofiber membrane, and said implant is inserted into said formed cavity.2. The process of claim 1 , wherein microgroves on said implant are coupled with growth factors immobilized collagen-poly-ε-caprolactone nanofiber matrix (CG-PCL NFM).3. The process of claim 1 , wherein fibronectin (FN) and magnesium oxide nanoparticles (MgO NPs) immobilized CG-PCL NFM coating are coupled on said implant.4. The process of claim 1 , further comprising immobilizing cell adhesion matrix protein (collagen claim 1 , fibronectin) and bone growth molecules (rhBMP claim 1 , TGF-β) using said ENF membrane to increase ...

Подробнее
Номер записи: 66
03-03-2022 дата публикации

Hemostatic Composition And Preparation Method Therefor

Номер: US20220062496A1
Автор: Chen Hao, FAN Jie, Shang Xiaoqiang, Xiao Liping, Yu Lisha
Принадлежит:

Provided is a hemostatic composition comprising trypsin and zeolite, wherein pore channels of the zeolite are micropores, the zeolite contains divalent metal cations, and the mass ratio of the trypsin to the zeolite is 1:200-4:10. In the present invention, the trypsin specifically binds to the zeolite, allowing the trypsin to maintain a certain conformation on the surface of the zeolite and to obtain a higher procoagulant activity, thereby obtaining a hemostatic composition with an excellent blood coagulation effect. The hemostatic composition of the present invention has the advantages of a simple preparation method, low cost and convenient use, and can be widely used in hemostasis during trauma and operations, especially in emergent hemostasis in hemophilia patients.

Подробнее
Номер записи: 67
19-02-2015 дата публикации

METHODS OF BREAST SURGERY

Номер: US20150051623A1
Автор: Bowley Melissa
Принадлежит: C.R. BARD, INC.

Surgical procedures of the breast where an adhesive is applied to fixate a reshaped and/or relocated portion of breast tissue. 1. A method of treating breast tissue , comprising:moving a first portion of breast tissue from a first location to a second location; andapplying an adhesive to retain the first portion of breast tissue at the second location.2. The method of claim 1 , wherein the adhesive is applied to the first portion of breast tissue.3. The method of claim 1 , wherein the adhesive is applied to an anatomical structure at the second location.4. The method of claim 3 , wherein the adhesive is applied to the anatomical structure before the first portion of breast tissue is moved to the second location.5. The method of claim 4 , further comprising contacting the first portion of breast tissue with the anatomical structure.6. The method of claim 2 , wherein the anatomical structure comprises at least one of skin overlying breast tissue claim 2 , breast tissue claim 2 , chest wall claim 2 , periosteum or skin at an upper pole portion of a breast.7. (canceled)8. The method of claim 2 , wherein the adhesive is applied to the first portion of breast tissue after the first portion of breast tissue is moved to the second location.9. The method of claim 1 , wherein the adhesive is applied to a prosthetic.10. The method of claim 9 , wherein the prosthetic is selected from the group consisting of a surgical repair fabric and a breast implant.11. (canceled)12. The method of claim 1 , wherein the second location is anatomically superior to the first location.13. The method of claim 1 , further comprising moving a second portion of breast tissue from a third location to a fourth location; andapplying an adhesive to retain the second portion of breast tissue at the fourth location.14. The method of claim 13 , wherein the second portion of breast tissue is placed adjacent to the first portion of breast tissue.15. The method of claim 14 , further comprising applying an ...

Подробнее
Номер записи: 68
25-02-2016 дата публикации

Implant and insertion device for an implant

Номер: US20160051194A1
Автор: Michael Diebold, Thomas Doerr
Принадлежит: Biotronik SE and Co KG

Embodiments include an implant for insertion into a human and/or animal body and an insertion device for the implant. The implant includes a housing, at least one negative pressure unit and at least one adhesive application unit to temporarily and/or permanently fix the implant to a bodily tissue.

Подробнее
Номер записи: 69
26-02-2015 дата публикации

BONE CEMENT COMPOSITION

Номер: US20150056289A1
Автор: Ueda Yoshimichi
Принадлежит:

The purpose of the present invention is to provide a bone cement composition which can have desired biological activity performance and desired radiolucency while enabling the strength of a cured product thereof to be kept. A titanium oxide coating is formed on radiolucent particles to thereby produce composite particles, and the composite particles are added to a bone cement composition. The bone cement composition thus produced can be used suitably for the filling of a bone defect portion and the fixation of an artificial joint and in percutaneous vertebroplasty. The shape of each of the radiolucent particles is preferably granular, and the titanium oxide is preferably of a rutile type. 1. A bone cement composition comprising:(a) a composite particle comprising a particle having radiopacity and a titanium dioxide coating with which the particle having radiopacity is coated, and(b) a base material formation component comprising a methacrylate polymer.2. The bone cement composition according to claim 1 , wherein the particle having radiopacity has a granular shape.3. The bone cement composition according to claim 1 , wherein the composite particle has a median diameter of 0.2 to 7 μm.4. The bone cement composition according to claim 1 , wherein the composite particle has a BET specific surface area of 1 to 30 m/g.5. The bone cement composition according to claim 1 , wherein the titanium dioxide coating comprises rutile titanium dioxide.6. The bone cement composition according to claim 1 , wherein the composite particle further comprises a silica coating.7. The bone cement composition according to claim 1 , wherein the particle having radiopacity is made of barium sulfate or zirconium dioxide.8. The bone cement composition according to claim 1 , wherein the titanium dioxide coating comprises 1 to 30% by weight of the composite particle.9. The bone cement composition according to claim 1 , wherein the titanium dioxide coating comprises 2 to 20% by weight of the ...

Подробнее
Номер записи: 70
26-02-2015 дата публикации

Adhesive Containing Microparticles

Номер: US20150056291A1
Автор: Johnson Peter, Wibaux Anne Marie
Принадлежит: AVERY DENNISON CORPORATION

Methods for forming and incorporating microparticles containing one or more active agents into adhesives are described. The methods involve spray drying a liquid of the one or more active agents and obtaining the active agent in a particulate form. The dry powder is then blended or otherwise incorporated with the adhesive of interest. Also described are various medical products utilizing the adhesive and one or more active agents in microparticle form, and related methods of use. 1. An adhesive composition comprising:an adhesive; andmicroparticles dispersed in the adhesive, the microparticles including a matrix material and at least one active agent.2. The adhesive of wherein the adhesive is selected from the group consisting of acrylic adhesives claim 1 , rubber adhesives claim 1 , silicone adhesives claim 1 , polyurethane adhesives claim 1 , and combinations thereof.3. The adhesive of wherein the adhesive is one of a solvent based adhesive and a hot melt adhesive.4. The adhesive of wherein the microparticles have an average span of from about 0.1 microns to about 500 microns.5. The adhesive of wherein the microparticles have an average span of from about 1 micron to about 200 microns.6. The adhesive of wherein the microparticles have an average span of from about 5 microns to about 100 microns.7. The adhesive of wherein the microparticles have an average span of from about 5 microns to about 50 microns.8. The adhesive of wherein the active agent is selected from the group consisting of pain reducing agents claim 1 , analgesics and anti-inflammatory agents claim 1 , corticosteriods claim 1 , antibiotics claim 1 , antimicrobial agents claim 1 , antifungal agents claim 1 , debriding agents claim 1 , antihistamines claim 1 , antiepileptics claim 1 , coronary vasodilators claim 1 , dermatologicals claim 1 , ancillary drugs claim 1 , and combinations thereof.9. The adhesive of wherein the active agent is a pain reducing agent.10. The adhesive of wherein the pain ...

Подробнее
Номер записи: 71
26-02-2015 дата публикации

THREE-DIMENSIONAL STRUCTURE PRODUCED FROM A MATERIAL CONTAINING POLYHYDROXYALKANOATE, KIT FOR PREPARATION OF BONE FILLER, AND INTRAMEDULLARY ROD

Номер: US20150057669A1
Автор: HIRATA Hitoshi, Kasuga Toshihiro, Natsume Tadahiro, Nishizuka Takanobu
Принадлежит: National University Corporation Nagoya University

Provided is a material for preventing bone cement from leaking out from bone during packing of the bone cement into a bone fracture site. The bone cement can be prevented from leaking out from the bone by employing a three-dimensional structure produced from a material containing a polyhydroxyalkanoate, when packing the bone cement into the bone fracture site. 110-. (canceled)11. A three-dimensional structure produced from material containing a polyhydroxyalkanoate , and adapted for preventing leakage of bone cement when the bone cement is injected into a bone fracture site.12. The three-dimensional structure according to claim 11 , wherein the polyhydroxyalkanoate is a copolymer of at least two monomers selected from 3-hydroxybutyric acid claim 11 , 3-hydroxyvaleric acid claim 11 , and 4-hydroxybutyric acid.1311. The three-dimensional structure according to claim claim 11 , wherein the three-dimensional structure is obtained by depositing fibers measuring -100 μm in diameter produced from the material containing the polyhydroxyalkanoate.14. The three-dimensional structure according to claim 12 , wherein the three-dimensional structure is obtained by depositing fibers measuring 1-100 μm in diameter produced from the material containing the polyhydroxyalkanoate.15. The three-dimensional structure according to claim 11 , wherein the three-dimensional structure extends by 200% or more.16. The three-dimensional structure according to claim 12 , wherein the three-dimensional structure extends by 200% or more.17. The three-dimensional structure according to claim 13 , wherein the three-dimensional structure extends by 200% or more.18. The three-dimensional structure according to claim 14 , wherein the three-dimensional structure extends by 200% or more.19. A kit for preparation of a bone filler claim 11 , including the three-dimensional structure according to claim 11 , and a bone cement.20. A kit for preparation of a bone filler claim 11 , including the three-dimensional ...

Подробнее
Номер записи: 72
10-03-2022 дата публикации

SURGICAL ADHESIVE ABLE TO GLUE IN WET CONDITIONS

Номер: US20220072195A1
Автор: Delmotte Yves A., Payssan Jonathan
Принадлежит:

Compositions and methods for sealing tissue of a patient in a wet environment are disclosed. 148.-. (canceled)49. A system comprising:a multi-chamber syringe assembly comprising:a first syringe;a second syringe;a syringe housing having two first orifices at a first end and two second orifices at a second end, the syringe housing holding both the first syringe and the second syringe in parallel so that outlets of both the first syringe and the second syringe extend through the first orifices of the first end of the syringe housing and a first plunger of the first syringe and a second plunger of the second syringe extend through the second orifices of the syringe housing;a syringe clip coupled to the first plunger of the first syringe and the second plunger of the second syringe;a transfer port closure adapter having two first inlets at a third end and one second inlet at a fourth end, the third end of the transfer port closure adapter configured to be attached to the first end of the syringe housing so that the outlets of both the first syringe and the second syringe are adapted to the two first inlets of the transfer port closure adapter; anda third syringe with its outlet adapted to the second inlet of the transfer port closure adapter;a first aqueous solution having a pH of about 1 to about 5.5 in the first syringe;a second aqueous solution having a pH of about 6 to about 11 in the second syringe;a dry powder composition comprising a first component having a polymer core substituted with at least two sulfhydryl groups and a second component having a polymer core substituted with at least two sulfhydryl-reactive groups in the third syringe.501. The system of claim , wherein the syringe clip is uncoupable from either the first plunger or the second plunger.511. The system of claim , wherein the transfer port closure adapter allows contents of the first syringe , the second syringe and the third syringe to be selectively mixed.521. The system of claim , wherein the ...

Подробнее
Номер записи: 73
21-02-2019 дата публикации

Implant

Номер: US20190053839A1
Автор: Brunner Christian, Voisard Cyril
Принадлежит: DePuy Synthes Products, Inc.

An implant includes a section made of polymer, wherein at least a portion of the section has a layer of a polymerizable and/or cross-linkable material. A method for fixation of a bone plate having several plate holes using the implant includes removing a cover sheet protecting the layer of polymerizable and/or cross-linkable material, activating the layer of polymerizable and/or cross-linkable material with electromagnetic energy or with moisture, introducing the implant into one of the plate holes of the bone plate when the bone plate is positioned on a bone, pressing on an end of the implant in order to contact the activated layer of polymerizable and/or cross-linkable material with the bone underneath the bone plate, and allowing the activated and pressurized layer of polymerizable and/or cross-linkable material to polymerize and/or cross-link and to adhere to the bone. 1. A method for fixation of a bone plate positioned on a bone and having at least one plate hole , the method comprising:providing a fixation implant comprising a front end, a rear end, and a layer of a polymerizable and/or cross-linkable material at the front end protected by a removable cover sheet;removing said removable cover sheet from the fixation implant;activating said polymerizable and/or cross-linkable material with electromagnetic energy or with moisture;introducing said fixation implant into the at least one plate hole of said bone plate positioned on a bone;applying pressure on said rear end of the fixation implant in order to contact said activated layer of said front end with a surface of the bone without penetrating the surface of the bone; andallowing said activated and pressurized layer to polymerize and/or cross-link and to adhere to the bone.2. The method according to claim 1 , wherein said fixation implant comprises a section made of a transparent polymer adjacent to the front end claim 1 , wherein activating said polymerizable and/or cross-linkable material occurs after ...

Подробнее
Номер записи: 74
03-03-2016 дата публикации

RADIOACTIVE BONE CEMENT

Номер: US20160058905A1
Автор: Kaneko Tadashi, Keyak Joyce H., Sehgal Varun, Skinner Harry B.
Принадлежит:

A target tissue can be treated with a radioisotope. Some methods for treating a target tissue with a radioisotope include determining a distance between a target tissue and a surface of a matrix material to be positioned adjacent the target tissue and, based on the determined distance, determining an activity to be mixed with the matrix material to obtain a desired activity concentration. Some methods further include mixing the radioisotope with the matrix material. In some embodiments, the matrix material comprises bone cement, and the target tissue is a tumor in a bone. The radioisotope may be a beta-emitting radioisotope mixed in the cement at a concentration to form a radioactive cement. 1. A method of placing a mixture for treating a target tissue in a vertebra , the method comprising:based on (a) an activity concentration of a radioisotope in the mixture, the mixture resulting from combining a matrix material and the radioisotope, and (b) a dose of radiation to be delivered to the target tissue by the radioisotope, determining a distance between the target tissue and a surface of the mixture;placing the mixture in the vertebra, wherein the mixture is configured such that, when the mixture is placed in the vertebra, and when a closest surface of the mixture is at the determined distance away from the target tissue, the mixture delivers substantially the dose to the target tissue independently of a total volume of the mixture placed in the vertebra.2. The method of claim 1 , wherein the mixture is configured such that claim 1 , when the mixture is placed in the vertebra claim 1 , only emissions from the radioisotope within about 2.5 mm of the closest surface reach the target tissue.3. The method of claim 1 , wherein the mixture is configured such that claim 1 , when the mixture is placed in the vertebra claim 1 , only emissions from the radioisotope within about 5 mm of the closest surface of the mixture reach the target tissue.4. The method of claim 1 , further ...

Подробнее
Номер записи: 75
03-03-2016 дата публикации

BONE TREATMENT SYSTEMS AND METHODS

Номер: US20160058906A1
Автор: Kohm Andrew, LUZZI Robert, Shadduck John, Truckai Csaba
Принадлежит:

The present disclosure relates to bone cement formulations that have an extended working time for use in vertebroplasty procedures and other osteoplasty procedures together with cement injectors that include energy delivery systems for on-demand control of cement viscosity and flow parameters. The bone cement formulations may include a liquid component having at least one monomer and a non-liquid component including polymer particles and benzoyl peroxide (BPO). The non-liquid component may be further configured to allow controlled exposure of the BPO to the liquid monomer so as to enable control of the viscosity of the bone cement composition. 1. A bone cement composition configured to provide a controlled viscosity , comprising:a liquid component comprising a monomer; anda non-liquid component comprising first polymer beads having a first average cross-sectional dimension and comprising a radical initiator at a first amount, and second polymer beads having a second average cross-sectional dimension greater than the first average cross-sectional dimension and comprising the radical initiator at a second amount lower than the first amount.2. The bone cement composition of claim 1 , wherein the initiator is dispersed throughout each of the first polymer beads and the second polymer beads.3. The bone cement composition of claim 1 , wherein the first average cross-sectional dimension is less than 100 microns claim 1 , and the second average cross-sectional dimension is greater than 100 microns.4. The bone cement composition of claim 1 , wherein the first polymer beads and the second polymer beads comprise polymethyl methacrylate polymer (PMMA).5. The bone cement composition of claim 4 , wherein the non-liquid component comprises less than 75 wt % PMMA on the basis of a total weight of the non-liquid component.6. The bone cement composition of claim 1 , wherein the radical initiator comprises benzoyl peroxide (BPO).7. The bone cement composition of claim 6 , wherein the ...

Подробнее
Номер записи: 76
21-02-2019 дата публикации

Hemostatic mixture of cellulose-based short and long fibers

Номер: US20190054203A1
Автор: Dwayne Looney, Erez Ilan, James Galloway, Nataly FREIZUS, Omri Faingold, Ronen Eavri, Sridevi Dhanaraj, Walter DANKER
Принадлежит: Ethicon Inc, Omrix Biopharmaceuticals Ltd

The invention relates to a hemostatic composition comprising a mixture of cellulose-based short and long fibers, preparation and use thereof.

Подробнее
Номер записи: 77
02-03-2017 дата публикации

MULTIBRANCHED BIOADHESIVE COMPOUNDS AND SYNTHETIC METHODS THEREFOR

Номер: US20170056548A1
Автор: Lee Bruce P., Murphy John L., Silvary Sunil
Принадлежит:

The invention describes new synthetic medical adhesives and antifouling coatings which exploit the key components of natural marine mussel adhesive proteins. 137.-. (canceled)38. A bioadhesive construct , comprising: a support suitable for tissue repair or reconstruction; anda multihydroxyphenyl (DHPD) functionalized polymer (DHPp), wherein the multihydroxyphenyl (DHPD) functionalized polymer (DHPp) is applied as a pattern, presenting coated and uncoated regions on the support.39. The bioadhesive construct of claim 38 , wherein the coated region provides initial bonding strength to secure in place the bioadhesive construct upon implantation claim 38 , and the uncoated region provides an unobstructed path for tissue ingrowth into the support.40. The bioadhesive construct of claim 38 , wherein the support comprises at least one of: a natural material and man made materials.41. The bioadhesive construct of claim 40 , wherein the natural material is selected from the group consisting of: collagen claim 40 , pericardium claim 40 , dermal tissues claim 40 , and small intestinal submucosa.42. The bioadhesive construct of claim 40 , wherein the man made material is selected from the group consisting of: polypropylene claim 40 , polyethylene claim 40 , polybutylene claim 40 , polyesters claim 40 , PTFE claim 40 , PVC claim 40 , polyurethanes and combinations thereof.43. The bioadhesive construct of claim 38 , wherein the support comprises tissue that has been cleaned and decellularized.44. The bioadhesive construct of claim 38 , wherein the support is a film claim 38 , a mesh claim 38 , a membrane claim 38 , a nonwoven or a prosthetic.45. The bioadhesive construct of claim 38 , further comprising an oxidant.46. The bioadhesive construct of claim 45 , wherein the oxidant is formulated with the coating.47. The bioadhesive construct of claim 45 , wherein the oxidant is applied to the coating.49. A bioadhesive construct claim 45 , comprising: a support suitable for tissue repair ...

Подробнее
Номер записи: 78
15-05-2014 дата публикации

POLYMETHYLMETHACRYLATE BONE CEMENT

Номер: US20140135418A1
Автор: VOGT Sebastian
Принадлежит:

The subject matter of the invention is a curable composition for use as bone cement, in particular for augmentation of osteoporotic bone tissue, comprising at least one organic polymer and at least one monomer for radical polymerisation, at least one particulate inorganic additive having a BET surface of at least 40 m/g, whereby the additive comprises covalently bound hydroxyl groups, whereby the composition further comprises at least one fatty acid ester or a mixture of fatty acid esters. Another subject matter of the invention is the use of said composition for augmentation of osteoporotic bone tissue and particularly preferably for vertebroplasty, kyphoplasty, and augmentation of drill holes in osteoporotic bone tissue, as well as a kit for producing said composition. 1. A composition for use as bone cement , comprising at least one organic polymer and at least one monomer for polymerisation , wherein the composition is curable and comprises:at least one monomer for radical polymerisation;{'sup': '2', 'at least one particulate inorganic additive having a BET surface of at least 40 m/g, whereby the additive comprises covalently bound hydroxyl groups; and'}at least one fatty acid ester or a mixture of fatty acid esters.2. Composition according to claim 1 , wherein the composition is a thixotropic and curable fluid or a thixotropic and curable paste.3. Composition according to claim 1 , wherein the at least one fatty acid ester or mixture of fatty acid esters is selected from (i) an ester from converting at least one fatty acid and a mono-alcohol claim 1 , diol claim 1 , triol or polyol each having 1 to 15 C atoms or a polyetherpolyol;(ii) a naturally occurring fatty acid ester or a fatty acid ester of natural origin; and(iii) a mixture containing fatty acid esters from (i) and (ii).4. Composition according to claim 1 , wherein the at least one fatty acid ester or mixture of fatty acid esters is liquid at room temperature (18-25° C.) or at body temperature (approx. ...

Подробнее
Номер записи: 79
15-05-2014 дата публикации

Collecting device for body fluids

Номер: US20140135720A1
Автор: BACH Anders, Buus Hasse, Stroebech Esben
Принадлежит: COLOPLAST A/S

A body waste collecting device includes a collecting pouch and an adhesive wafer for attachment to the body. The adhesive wafer includes a backing layer, a first adhesive and a second adhesive. The second adhesive includes a polar plasticising oil or a combination of polar plasticising oils in the content of above 10% (w/w) of the second adhesive, and at least one polar polyethylene copolymer, where the content of the polyethylene copolymer is 10-50% (w/w) of the second adhesive, and the polyethylene copolymer has a melt flow index below 2 g/10 min (190° C./21.1N). 2. The collecting device according to claim 1 , wherein the second adhesive in continuous form exhibiting a moisture vapour transmission rate of at least 100 g/m/day for a 150 μm adhesive sheet when measured according to MVTR Test Method.3. The collecting device according to claim 1 , wherein the polar polyethylene copolymer is selected from the group consisting of ethylene vinyl acetate claim 1 , ethylene vinyl acetate carbon monoxide claim 1 , ethylene butyl acetate claim 1 , ethylene vinyl alcohol claim 1 , ethylene butyl acrylate claim 1 , ethylene butyl acrylate carbon monoxide claim 1 , and combinations thereof.4. The collecting device according to claim 3 , wherein the polar polyethylene copolymer is ethylene vinyl acetate.5. The collecting device according to claim 4 , wherein the ethylene vinyl acetate has a content of at least 40% (w/w) vinyl acetate preferably with 40-80% (w/w) vinyl acetate.6. The collecting device according to claim 1 , wherein the content of the polar polyethylene copolymer is 10-45% (w/w) of the second adhesive preferably 15-30%.7. The collecting device according to claim 1 , wherein the polar polyethylene copolymer has a molecular weight of above 250 claim 1 ,000 g/mol.8. The collecting device according to claim 1 , wherein the polar plasticising oil is selected from the group of liquid rosin derivatives claim 1 , aromatic olefin oligomers claim 1 , vegetable and animal ...

Подробнее
Номер записи: 80
20-02-2020 дата публикации

EMBOLIC MATERIAL AND METHOD FOR PRODUCING SAME

Номер: US20200054783A1
Автор: BITO Kenta, HASEBE Terumitsu, Hotta Atsushi
Принадлежит:

An embolic material contains at least one type of polymer and a liposoluble contrast medium. A method for producing an embolic material includes extruding a raw material that is in a molten state into a solvent, and cooling the raw material so as to solidify the raw material. The raw material contains a polymer and a liposoluble contrast medium. 1. An embolic material comprising:at least one type of polymer: anda liposoluble contrast medium.2. The embolic material according to claim 1 ,wherein the liposoluble contrast medium can contain a pharmaceutical drug.3. The embolic material according to claim 1 ,wherein the polymer is biodegradable.4. The embolic material according to claim 1 ,wherein the polymer is one or more selected from a group consisting of polycaprolactone, polylactate, a copolymer of polycaprolactone and polylactate, a mixture of polycaprolactone and polylactate, and a compound of polycaprolactone and polylactate.5. A method for producing an embolic material claim 1 , the method comprising:extruding a raw material containing at least one type of polymer and a liposoluble contrast medium into a solvent, the raw material being in a molten state; andcooling the raw material so as to solidify the raw material.6. The method for producing an embolic material according to claim 5 ,wherein the raw material extruded into the solvent forms spherical shapes.7. The method for producing an embolic material according to claim 5 ,wherein the liposoluble contrast medium can contain a pharmaceutical drug.8. The method for producing an embolic material according to claim 5 ,wherein the polymer is biodegradable.9. The method for producing an embolic material according to claim 5 ,wherein the polymer is one or more selected from a group consisting of polycaprolactone, polylactate, a copolymer of polycaprolactone and polylactate, a mixture of polycaprolactone and polylactate, and a compound of polycaprolactone and polylactate. This international application claims the ...

Подробнее
Номер записи: 81
20-02-2020 дата публикации

Ionic polymers and their use as wet-adhesives and coatings

Номер: US20200056076A1
Автор: Byung Jun AHN, Roscoe Linstadt, Sam Linh Nguyen
Принадлежит: Acatechol Inc

The present application discloses an adhesive composition comprising a polymer of the formulae A, B and C: and methods for using the adhesive composition. wherein x and y define the block polymer and are integer greater than 1.

Подробнее
Номер записи: 82
28-02-2019 дата публикации

METHODS FOR VAS-OCCLUSIVE CONTRACEPTION AND REVERSAL THEREOF

Номер: US20190060513A1
Автор: Eisenfrats Kevin Simon, Herr John C., Klibanov Alexander L.
Принадлежит:

Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention. 1. A composition comprising:one or more species with a diameter of 0.1 to 1 μm in solvent;wherein the one or more species are capable of forming an implantable network with pores with a diameter of less than or equal to 3 μm;wherein the one or more species and/or the implantable network are capable of being injected into a bodily lumen; andwherein the implantable network has a permanent lifespan in vivo.2. The composition of claim 1 , wherein one or more of the species comprises one or more of natural or synthetic monomers claim 1 , polymers claim 1 , copolymers or block copolymers claim 1 , biocompatible monomers claim 1 , polymers claim 1 , copolymers or block copolymers claim 1 , polystyrene claim 1 , neoprene claim 1 , polyetherether 10 ketone (PEEK) claim 1 , carbon reinforced PEEK claim 1 , polyphenylene claim 1 , polyetherketoneketone (PEKK) claim 1 , polyaryletherketone (PAEK) claim 1 , polyphenylsulphone claim 1 , polysulphone claim 1 , polyurethane claim 1 , polyethylene claim 1 , low-density polyethylene (LDPE) claim 1 , linear low-density polyethylene (LLDPE) claim 1 , high-density polyethylene (HDPE) claim 1 , polypropylene claim 1 , polyetherketoneetherketoneketone (PEKEKK) claim 1 , nylon claim 1 , fluoropolymers claim 1 , polytetrafluoroethylene (PTFE or TEFLON®) claim 1 , TEFLON® TFE (tetrafluoroethylene) claim 1 , polyethylene terephthalate (PET or PETE) claim 1 , TEFLON® FEP (fluorinated ethylene propylene) claim 1 , ...

Подробнее
Номер записи: 83
28-02-2019 дата публикации

Hemostatic Composition

Номер: US20190060514A1
Автор: Dwayne Looney, Erez Ilan, James Galloway, Nataly FREIZUS, Omri Faingold, Ronen Eavri, Sridevi Dhanaraj, Walter DANKER
Принадлежит: Ethicon Inc, Omrix Biopharmaceuticals Ltd

The present invention relates to improved hemostatic compositions comprising cellulose-based fibers supplemented with compounds, preparation and use thereof.

Подробнее
Номер записи: 84
28-02-2019 дата публикации

POLYMER PARTICLES

Номер: US20190062479A1
Автор: Cruise Gregory M., Harris Clayton, Hincapie Gloria
Принадлежит:

Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents. 1. A polymer particle comprising:at least one monomer; andat least one crosslinker;wherein the polymer particle has a diameter between about 40 μm and about 1,200 μm and is susceptible to degradation through hydrolysis or enzymatic action, and wherein the degradation provides less than about 10% of the polymer particle intact after about 2 weeks.2. The polymer particle of claim 1 , wherein the polymer particle has a diameter between about 75 μm and about 1 claim 1 ,200 μm.3. The polymer particle of claim 1 , wherein the at least one monomer includes a functional group.4. The polymer particle of claim 3 , wherein the functional group is acrylate claim 3 , acrylamide claim 3 , methacrylate claim 3 , or methacrylamide.5. The polymer particle of claim 3 , wherein the functional group is an acidic ionizable functional group or a basic ionizable functional group.6. The polymer particle of claim 1 , wherein the at least one crosslinker includes at least two functional groups.7. The polymer particle of claim 1 , wherein the at least one crosslinker includes at least one linkage susceptible to degradation through hydrolysis or enzymatic action.9. The polymer particle of claim 7 , wherein the at least one linkage is an ester claim 7 , a thioester claim 7 , a carbonate claim 7 , a peptide cleavable by matrix metalloproteinases claim 7 , a peptide cleavable by matrix collagenases claim 7 , a peptide cleavable by matrix elastases claim 7 , a peptide cleavable by matrix cathepsins claim 7 , or a combination thereof.10. The polymer particle of claim 7 , including a second crosslinker including a second linkage selected from an ester claim 7 , a thioester claim 7 , a carbonate claim 7 , a peptide cleavable by matrix metalloproteinases claim 7 , a peptide cleavable by matrix collagenases claim 7 , a peptide cleavable by matrix ...

Подробнее
Номер записи: 85
12-03-2015 дата публикации

WOUND HEALING COMPOSITIONS INCLUDING CYANOACRYLATE MONOMERS AND PHENYTOIN

Номер: US20150071869A1
Автор: Ruiz, SR. Rafael, Zhang Sheng
Принадлежит:

A monomeric adhesive composition includes a stabilized polymerizable monomer, such as a 1,1-disubstituted monomer, including a cyanoacrylate, and a wound healing agent, wherein the wound healing agent is 5,5-disubstitutedhydantoin, including phenytoin; and a method for making said composition. 1. A composition , comprising 2-octyl cyanoacrylate monomer , an amount of butylated hydroxyl anisole and sulfur dioxide effective to stabilize the 2-octyl cyanoacrylate monomer , and 0.05% to 0.3% by weight of the composition of phenytoin , wherein the composition is a homogeneous mixture.2. The composition of claim 1 , wherein said composition is sterilized claim 1 , and the viscosity of the sterilized composition increases between about 0% and about 40% after sterilization relative to the viscosity of the composition prior to sterilization.3. The composition of claim 1 , further comprising up to 2000 ppm of a polymerization accelerator comprising 18-crown-6 crown ether.4. The composition of claim 1 , further comprising a plasticizing agent selected from the group consisting of tributyl citrate claim 1 , diisodecyl adipate and acetyl tributyl citrate.5. The composition of claim 1 , further comprising a thickening agent selected from the group consisting of a partial polymer of a cyanoacrylate and a triblock copolymer of polyoxyalkylene.6. The composition of claim 2 , wherein the composition is sterilized by irradiation.7. The composition of claim 6 , wherein the composition is sterilized by E-beam irradiation.8. The composition of claim 1 , wherein the composition comprises 0.1% to 0.2% by weight of the composition of phenytoin.9. A kit claim 1 , comprising an applicator and the composition of .10. A method of treating tissue claim 1 , comprising applying the adhesive composition of to a tissue surface claim 1 , and allowing said composition to polymerize on said tissue surface.11. A composition claim 1 , comprising n-butyl cyanoacrylate monomer claim 1 , an amount of ...

Подробнее
Номер записи: 86
17-03-2016 дата публикации

EMULSIONS OR MICROEMULSIONS FOR USE IN ENDOSCOPIC MUCOSAL RESECTIONING AND/OR ENDOSCOPIC SUBMUCOSAL DISSECTION

Номер: US20160074554A1
Автор: FRIMONTI Enrico, LONGO Luigi Maria, Moro Luigi, REPICI Alessandro
Принадлежит: COSMO TECHNOLOGIES LTD.

The present invention relates to a pharmaceutical composition in form of emulsion or microemulsion and the use thereof as aid during endoscopic procedures in which it is injected in a target tissue in order to form a cushion. More in details, the invention relates to a method for performing an endoscopic procedure, which comprises injecting said pharmaceutical composition in form of emulsion or microemulsion in a target tissue of a patient, in order to form a cushion, which cushion is then optionally subjected to an endoscopic surgical procedure, such as a resection. 1. A pharmaceutical composition in the form of an emulsion or a microemulsion comprising:(a) an aqueous phase;(b) an oily phase;(c) at least one surfactant;(d) at least one of poloxamer 188, poloxamer 407 or a mixture of poloxamer 188 and poloxamer 407; and(e) at least one physiologically acceptable excipient;wherein said at least one of poloxamer 188, polyoxamer 407 or a mixture of poloxamer 188 and poloxamer 407 is present in an amount below the critical gelation concentration (CGC), and wherein said composition remains in liquid phase up to a temperature of about 40° C. in vitro.2. The pharmaceutical composition according to claim 1 , wherein said composition has a viscosity below about 150 cP (centipoises).3. The pharmaceutical composition according to claim 1 , wherein said at least one of poloxamer 188 claim 1 , poloxamer 407 or a mixture of poloxamer 188 and poloxamer 407 is present in an amount below about 15% by weight claim 1 , with respect to the weight of the composition.4. The pharmaceutical composition in form of emulsion or microemulsion according to claim 1 , wherein said at least one of poloxamer 188 claim 1 , polyoxamer 407 or a mixture of poloxamer 188 and poloxamer 407 is present in an amount between about 5% and about 11% by weight claim 1 , with respect to the weight of the composition.5. The pharmaceutical composition according to claim 1 , wherein said poloxamer 407 is present in ...

Подробнее
Номер записи: 87
17-03-2016 дата публикации

SIMPLE COACERVATES AND METHODS OF USE THEREOF

Номер: US20160074556A1
Автор: Stewart Russell J.
Принадлежит: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Described herein is the synthesis of adhesive from simple adhesive coacervates and their uses thereof. The adhesives are produced by (a) preparing a solution comprising (1) a polyelectrolyte, wherein the polyelectrolyte comprises a polyanion or polycation but not a combination thereof, the polyeletrolyte comprises at least one crosslinking group, and (2) a sufficient amount of a complimentary counterion to produce a simple adhesive coacervate; and (b) crosslinking the simple adhesive coacervate to produce the adhesive. The adhesives have numerous medical and non-medical applications. 1. A method for producing an adhesive in a subject comprising(a) introducing into the subject a simple coacervate comprising a polyelectrolyte, wherein the polyelectrolyte comprises a polyanion or polycation but not a combination thereof, and the polyelectrolyte comprises at least one crosslinking group capable of covalently crosslinking with itself, and (2) a sufficient amount of a complimentary multivalent cation or multivalent anion to produce the simple coacervate; and(b) covalently crosslinking the polyelectrolyte in the simple coacervate to produce the adhesive in the subject.2. The method of for closing or sealing a puncture in an internal tissue or membrane of the subject comprising (a) applying the simple coacervate to the puncture and (b) covalently crosslinking the polyelectrolyte in the simple coacervate.3. The method of for closing or sealing a puncture in internal tissue or membrane in the subject by adhering a scaffold to or within the puncture with the simple coacervate and subsequently covalently crosslinking the polyelectrolyte in the simple coacervate.4. The method of wherein the simple coacervate is introduced into a blood vessel and subsequently covalently crosslinking the polyelectrolyte in the simple coacervate to partially or completely block the vessel.5. The method of wherein the simple coacervate is applied to a fractured bone and subsequently covalently ...

Подробнее
Номер записи: 88
24-03-2022 дата публикации

Blood Coagulation-Promoting Silk Fibroin-Polypeptide Electrospun Membrane and Preparation Method Thereof

Номер: US20220088266A1
Автор: Lei Fang, Shuai Yajun, Yang Mingying
Принадлежит:

The present invention discloses a blood coagulation-promoting silk fibroin-polypeptide electrospun membrane and a preparation method thereof. The electrospun membrane is made by using silkworm silk fibroin as a carrier and adding the polypeptide GPRPPSEHLQIT. It is mainly used for promoting blood coagulation, and is a blood coagulation material that can targetedly bind to human fibrinogen. The preparation method includes the steps of dissolving, filtering, dialyzing, concentrating and freeze-drying silkworm cocoons after degumming to obtain silk fibroin freeze-dried powder. The polypeptide used in the present invention is a polypeptide obtained by self-screening. Compared with other polypeptides, it can specifically targetedly bind to human fibrinogen. 1. A blood coagulation-promoting silk fibroin-polypeptide electrospun membrane , wherein the polypeptide has a sequence of GPRPPSEHLQIT (SED ID NO: 1).2. The silk fibroin-polypeptide electrospun membrane according to claim 1 , wherein the electrospun membrane is made of interwoven silk fibroin nanofibers claim 1 , and the polypeptide is evenly distributed in the nanofibers.3. A preparation method of the blood coagulation-promoting silk fibroin-polypeptide electrospun membrane according to claim 1 , wherein specific preparation steps adopted are as follows:1) dissolving, filtering, dialyzing, concentrating, freeze-drying silkworm cocoons after degumming to obtain silk fibroin freeze-dried powder;2) evenly mixing the silk fibroin freeze-dried powder and the polypeptide GPRPPSEHLQIT (SED ID NO: 1) with a hexafluoroisopropanol solvent;3) electrospinning a mixed solution obtained in step 2) to obtain a silk fibroin-polypeptide electrospun membrane.4. The preparation method of the silk fibroin-polypeptide electrospun membrane according to claim 3 , wherein the mass ratio of the silk fibroin freeze-dried powder:the hexafluoroisopropanol solvent used in the step 2) is 2: 98-20:80.5. The preparation method of the silk fibroin- ...

Подробнее
Номер записи: 89
07-03-2019 дата публикации

OILY COMPOSITIONS

Номер: US20190070332A1
Автор: CAINE Marcus Gordon, CHUNG Shui Ting, DREHER Matthew R., LEWIS Andrew Lennard, Willis Sean Leo
Принадлежит: BIOCOMPATIBLES UK LIMITED

The present invention provides emulsion compositions comprising an continuous oil phase, a discontinuous aqueous phase and a plurality of microparticles. The composition may comprise a pharmaceutical active ingredient located in the oil phase, the particulate phase or the aqueous phase. The emulsion compositions have improved stability and coherence and are useful in the treatment of tumours by embolotherapy. 1. An emulsion composition comprising a continuous phase , a discontinuous phase and a plurality of particles , the discontinuous phase being aqueous and the continuous phase comprising an oil;wherein the particles comprise a polymer to which iodine is covalently bound.2. An emulsion composition comprising a continuous phase , a discontinuous phase and a plurality of particles , the discontinuous phase being aqueous and the continuous phase comprising an oil;wherein the particles are sufficiently hydrophobic such that an emulsion prepared according to example 2 herein, using a lipiodol:aqueous phase ratio of 2:1 and in which the aqueous phase contains no contrast agent, is stable for at least 10 minutes at between 18 and 22° C.3. An emulsion composition comprising a continuous phase , a discontinuous phase and a plurality of particles , the discontinuous phase being aqueous and the continuous phase comprising an oil;wherein the particles, when measured according to Example 4a herein, have a cantilever deflection (measured in volts) of less than that of DC Bead.4. A composition according wherein the particles comprise a polymer to which iodine is covalently bound.5. A composition according to wherein the iodine is bound to an aromatic group claim 1 , which aromatic group is covalently bound to the polymer.6. A composition according to wherein particles comprise a polymer to which iodine is covalently bound claim 1 , and wherein the iodine is present in the particles at a level of at least 30 mg I/ml of packed volume claim 1 , preferably 60 mg iodine per ml PV.7. ...

Подробнее
Номер записи: 90
16-03-2017 дата публикации

CYANOACRYLATE ADHESIVE COMPOSITION AND METHOD FOR MAKING THE SAME

Номер: US20170072092A1
Автор: CHU Fa-Ter
Принадлежит:

The present invention provides a method for making an adhesive composition. An adhesive substrate comprising at least a first cyanoacrylate monomer is provided and then mixed with a thickening agent containing polycyanoacrylate prepared by polymerization of a second cyanoacrylate monomer initiated with an aqueous solution of ammonium hydroxide or alcohol. In light of low boiling point of ammonium hydroxide and alcohol, they can be easily removed by heating at low temperature. As such, conventional premature polymerization of adhesive substrate owing to addition of a thickening agent containing residual accelerators can be overall improved. 1. A method of making an adhesive composition , comprising the steps of:(a) providing an adhesive substrate, the adhesive substrate comprising at least a first cyanoacrylate monomer; providing a second cyanoacrylate monomer;', 'adding an aqueous solution of ammonium hydroxide or alcohol into the second cyanoacrylate monomer to initiate polymerization and forming a polymer of the second cyanoacrylate monomer; and', 'heating and drying the polymer of the second cyanoacrylate monomer at 30° C-100° C. to remove the ammonium hydroxide or the alcohol; and, '(b) providing a thickening agent, the thickening agent comprising at least a polycyanoacrylate, wherein the polycyanoacrylate is prepared by a method comprising the steps of(c) mixing the thickening agent with the adhesive substrate.2. The method according to claim 1 , wherein the first cyanoacrylate monomer or the second cyanoacrylate monomer is selected from the group consisting of alkyl 2-cyanoacrylate claim 1 , cycloalkyl-2-cyanoacrylate claim 1 , fluoroalkyl-2-cyanoacrylate claim 1 , fluorocycloalkyl-2-cyanoacrylate claim 1 , alkoxyalkyl-2-cyanoacrylate claim 1 , alkoxycycloalkyl-2-cyanoacrylate claim 1 , fluoroalkoxyalkyl-2-cyanoacrylate claim 1 , and mixtures of two or more thereof.3. The method according to claim 2 , wherein the first cyanoacrylate monomer or the second ...

Подробнее
Номер записи: 91
16-03-2017 дата публикации

Polymethylmethacrylate bone cement with adjustable initial viscosity, and method for producing a bone cement dough with variable initial viscosity

Номер: US20170072093A1
Автор: Sebastian Vogt, Thomas Kluge
Принадлежит: HERAEUS MEDICAL GMBH

A polymerizable polymethylmethacrylate bone cement, in which the initial viscosity of the cement dough can be controlled. The polymerizable bone cement composition comprises a monomer for radical polymerization, a powdered polymethylmethacrylate-co-polymer soluble in the monomer or a mixture comprising polymethylmethacrylate-co-polymers, a polymerization initiator, and a radiopaquer, wherein the powdered polymethylmethacrylate-co-polymer comprises at least one particulate polymethylmethacrylate-co-polymer having a molar mass of more than or equal to 200,000 g/mol, and the polymethylmethacrylate-co-polymer is obtainable by polymerization of a mixture of 90.0% or more by weight methylmethacrylate and 10.0% or less by weight of one or more comonomers, wherein the weight ratio of component A comprising the polymethylmethacrylate-co-polymer, radiopaquer, and polymerization initiator, and component B comprising a monomer for radical polymerization, stabiliser, and polymerization accelerator, is approximately 2.0 to 3.4 to 1.0, for controlling the initial viscosity of the bone cement dough formed by mixing components A and B.

Подробнее
Номер записи: 92
14-03-2019 дата публикации

Particles

Номер: US20190076571A1
Автор: Gregory M. Cruise, Steve Plotkin, Xinping Wu
Принадлежит: MicroVention Inc

Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.

Подробнее
Номер записи: 93
14-03-2019 дата публикации

CATIONIC STEROIDAL ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF DERMAL TISSUE

Номер: US20190076581A1
Автор: Bracken Ronald, Genberg Carl, Savage Paul B.
Принадлежит:

This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application. 1. A dermal filler composition for injection into dermal tissue , comprising:a biologically compatible dermal filler material in the form of a liquid, gel, paste, or viscous material so as to be syringe-injectable into dermal tissue; andone or more cationic steroidal antimicrobial (CSA) compounds incorporated into the biologically compatible dermal filler material so that, when injected into soft tissue, the dermal filler composition can form a bolus having a reservoir of CSA compounds incorporated into and distributed within a matrix of the dermal filler composition and provide effective time release of the one or more CSA compounds from the dermal filler material.2. The dermal filler composition of claim 1 , wherein the dermal filler comprises one or more syringe-injectable bioabsorbable materials.3. The dermal filler composition of claim 1 , wherein the dermal filler comprises syringe-injectable hyaluronic acid.4. The dermal filler composition of claim 1 , wherein the dermal filler comprises syringe-injectable collagen.5. The dermal filler composition of claim 1 , wherein the dermal filler comprises syringe-injectable hydroxyapatite mineral.6. ...

Подробнее
Номер записи: 94
24-03-2016 дата публикации

Method for Producing an Antibiotic Polymethylmethacrylate Bone Cement Powder, and an Antibiotic Polymethylmethacrylate Bone Cement Powder

Номер: US20160082143A1
Автор: VOGT Sebastian
Принадлежит:

The invention relates to a method for producing an antibiotic bone cement, whereby, in a step A), a bone cement base powder with a water content of less than or equal to 1.0% by weight is mixed with trometamol-fosfomycin to form a bone cement powder, and, in a step X), the bone cement powder is dried to a water content of less than or equal to 1.0% by weight. The invention also relates to a bone cement powder that was produced according to said method and contains a bone cement base powder and trometamol-fosfomycin, whereby the bone cement powder has a water content of less than or equal to 1.0% by weight. The bone cement powder is free-flowing and does not clump and can be used for producing bone cements that meet ISO 5833. 1. A method for producing an antibiotic bone cement , comprising:step A), mixing a bone cement base powder with a water content of less than or equal to 1.0% by weight with trometamol-fosfomycin to form a bone cement powder, and,step X), drying the bone cement powder to a water content of less than or equal to 1.0% by weight.2. The method according to claim 1 , wherein the bone cement base powder is a polymer powder comprising a polymer selected from the group consisting of poly(methacrylic acid methylester) claim 1 , poly(methacrylic acid ethylester) claim 1 , poly(methylmethacrylic acid propylester) claim 1 , poly(methacrylic acid isopropylester) claim 1 , poly(methyl-methacrylate-co-methylacrylate) claim 1 , poly(styrene-co-methylmethacrylate) claim 1 , and a mixture of at least two of said polymers.3. The method according to claim 1 , wherein claim 1 , in step A) claim 1 , the amount of bone cement base powder that is admixed to the bone cement powder ranges from 70 to 99.5% by weight.4. The method according to claim 1 , wherein a radiopaquer is additionally admixed to the bone cement powder in step A).5. The method according to claim 4 , wherein the amount of admixed radiopaquer is in the range from 3 to 30% by weight.6. The method ...

Подробнее
Номер записи: 95
26-03-2015 дата публикации

Compliant Surgical Adhesive

Номер: US20150086503A1
Автор: Mefford Olin Thompson, Nagatomi Jiro, Sanders Lindsey, Stone Roland, Webb C. Kenneth
Принадлежит:

Surgical adhesives that include a blend of two different thermoreversible gelling polymers and a crosslinking agent are described. The first thermoreversible gelling polymer is partially or fully acrylated and the second thermoreversible gelling polymer includes dual functionality including acrylate functionality and amine-reactive functionality. The adhesives can provide gelling and covalent crosslinking within the polymers of the adhesive as well as crosslinking with surrounding tissue. 1. A gel-forming composition comprising:a first thermoreversible gelling block copolymer that includes a hydrophilic block and a hydrophobic block, the first thermoreversible gelling copolymer including acrylate functionality in at least a portion of the termini of the copolymer;a second thermoreversible gelling block copolymer that differs from the first thermoreversible gelling block copolymer and includes a hydrophilic block and a hydrophobic block, the second thermoreversible gelling copolymer including acrylate functionality on a portion of the termini of the copolymer and including amine-reactive functionality on a portion of the termini, the hydrophilic block of the second thermoreversible gelling block copolymer being the same or different as the hydrophilic block of the first thermoreversible gelling block copolymer and the hydrophobic block of the second thermo reversible gelling block copolymer being the same or different as the hydrophobic block of the first thermoreversible gelling block copolymer; anda polyfunctional thiol crosslinker;the composition comprising the first thermoreversible gelling block copolymer and the second thermoreversible gelling block copolymer in a blend at a ratio of from about 10:90 to about 90:10 by weight, respectively.2. The composition of claim 1 , wherein the first and/or the second thermoreversible gelling block copolymer includes a polyethylene oxide as the hydrophilic block.3. The composition of claim 1 , wherein the first and/or the ...

Подробнее
Номер записи: 96
12-03-2020 дата публикации

PANCREATIC FISTULA OCCLUSION

Номер: US20200078489A1
Автор: Kobayashi Satoru
Принадлежит:

Methods and materials for occluding a pancreatic fistula are described herein. One method for occluding a pancreatic fistula includes administering an effective amount of a self-assembling peptide solution to a pancreatic fistula, where the self-assembling peptide is between about 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions, thereby occluding the pancreatic fistula. 1. A method for occluding a pancreatic fistula , the method comprising administering an effective amount of a self-assembling peptide solution to a pancreatic fistula , wherein the self-assembling peptide is between about 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions , thereby occluding pancreatic fistula.2. The method of claim 1 , wherein the self-assembling peptide comprises about 12 to about 16 amino acids that alternate between hydrophobic and a hydrophilic amino acids.3. The method of claim 1 , wherein the self-assembling peptide comprises a sequence selected from RADA claim 1 , IEIK claim 1 , TTTT claim 1 , ATAT claim 1 , TVTV claim 1 , ASAS claim 1 , SSSS claim 1 , VVVTTTT claim 1 , and a combination thereof.4. The method of claim 1 , wherein the self-assembling peptide comprises a sequence selected from (RADA) claim 1 , (IEIK)I claim 1 , and (KLDL).5. The method of claim 1 , wherein the self-assembling peptide is about 0.1 to about 10 w/v % of the solution or about 0.1 to about 3.5 w/v % of the solution.6. The method of claim 1 , wherein the self-assembling peptide is about 1 claim 1 , about 2.5 claim 1 , or about 3 w/v % of the solution.7. The method of claim 1 , wherein the effective amount is approximately 0.1 mL per 1 cmto approximately 5 mL per 1 cmof target area.8. The method of claim 1 , wherein the effective amount is approximately 1 mL per 1 cmof target area.9. The method of claim 1 , wherein the hydrogel is formed ...

Подробнее
Номер записи: 97
12-06-2014 дата публикации

STERILIZED LIQUID COMPOSITIONS OF CYANOACRYLATE MONOMER MIXTURES

Номер: US20140163610A1
Автор: Zhang Sheng
Принадлежит: Adhezion Biomedical, LLC

Cyanoacrylate adhesive compositions comprise a mixture of two cyanoacrylate monomers, including 2-octyl cyanoacrylate and n-butyl cyanoacrylate. The monomers are stabilized and sterilized by irradiation, and do not substantially increase in viscosity after sterilization or after two years of shelf storage. These compositions have anti-microbial properties, and may be used to close wounds as well as secure catheters inserted into the body in place. 1. A method for closing a skin ulcer , comprising applying a cyanoacrylate adhesive composition to the skin ulcer and allowing the composition to cure on the ulcer , thereby closing the ulcer , wherein the composition comprises a mixture of about 78% to about 82% by weight of monomeric 2-octyl cyanoacrylate , about 22% to about 18% by weight of monomeric n-butyl cyanoacrylate , about 2000 ppm to about 14 ,000 ppm of butylated hydroxyl anisole , and about 10 ppm to about 200 ppm of sulfur dioxide or about 5 ppm to about 50 ppm of an acid stabilizer selected from the group consisting of sulfuric acid , phosphoric acid , and perchloric acid , wherein the composition is sterilized by electron beam (E-beam) irradiation , wherein the viscosity of the sterilized composition increases by no more than about 300% over a period of at least two years of shelf storage , and wherein the composition does not contain any plasticizer.2. The method of claim 1 , wherein the skin ulcer comprises a pressure ulcer.3. The method of claim 2 , wherein the pressure ulcer comprises a bed sore.4. The method of claim 1 , wherein the composition comprises a mixture of about 79% to about 81% by weight of monomeric 2-octyl cyanoacrylate claim 1 , about 21% to about 19% by weight of monomeric n-butyl cyanoacrylate claim 1 , about 2000 ppm to about 14 claim 1 ,000 ppm of butylated hydroxyl anisole claim 1 , and about 10 ppm to about 200 ppm of sulfur dioxide.5. The method of claim 1 , wherein the composition comprises a mixture of about 79% to about 81% by ...

Подробнее
Номер записи: 98
29-03-2018 дата публикации

POLYMER PARTICLES

Номер: US20180085487A1
Автор: Cruise Gregory M., Hincapie Gloria, Wu Xinping, Wu Yue
Принадлежит:

Described are polymers and methods of forming and using same. 1. A particle including:at least one monomer amenable to polymerization;at least one crosslinker; andat least one pharmaceutical agent chemically bonded to the particle with a hydrolytically degradable linkage.2. The particle of claim 1 , wherein the particle is biostable.3. The particle of claim 1 , wherein the crosslinker is biostable.4. The particle of claim 1 , wherein the particle is biodegradable.5. The particle of claim 1 , wherein the at least one monomer amenable to polymerization includes glycerol monomethacrylate.6. The particle of claim 1 , wherein the at least one monomer amenable to polymerization includes dimethyl acrylamide.7. The particle of claim 1 , wherein the crosslinker is biodegradable.19. A method of forming a particle of comprising:reacting a prepolymer solution including the dimethyl acrylamide, the glycerol monomethacrylate, the at least one crosslinker, and the at least one pharmaceutical agent, andforming the particle.20. A method of treating a vessel comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering to the vessel a plurality of particles according to .'} This application claims the benefit of U.S. provisional patent application No. 62/401,091, filed Sep. 28, 2016 and U.S. provisional patent application No. 62/428,990, filed Dec. 1, 2016, the entire disclosures each of which is incorporated herein by reference.Described herein are polymeric particles configured for intravascular delivery of pharmaceutical agents, e.g., to a diseased site. Preparation of these polymer particles is also described.Described herein are polymer particles. In some embodiments, the particles are hydrogel particles. These particles can be configured to deliver pharmaceutical agents and can also be used for embolization. In some embodiments, the polymers used herein can include at least one monomer amenable to polymerization, at least one crosslinker, and at least one ...

Подробнее
Номер записи: 99
21-03-2019 дата публикации

COMPOSITE BIOADHESIVE SEALANT

Номер: US20190083676A1
Автор: PINKAS Oded, ZILBERMAN Meital
Принадлежит:

A kit and a bioadhesive, comprising gelatin, alginate, montmorillonite and a coupling agent, which is characterized by rapid curing, optimal viscosity, high burst strength, flexibility, biocompatibility and biodegradability, is disclosed. 1. A kit for forming a bioadhesive , comprising a first container containing a first formulation and a second container containing a second formulation , said first formulation comprises gelatin and alginate and said second formulation comprises a coupling agent for coupling said gelatin and/or for coupling said alginate and/or for coupling said gelatin to said alginate , wherein at least one of said first formulation and said second formulation comprises montmorillonite.2. The kit of claim 1 , wherein a concentration of said gelatin in a bioadhesive obtained by combining said first formulation and said second formulation at volume ratio of 1:9 to 25:1 claim 1 , ranges from 50 mg/ml to 500 mg/ml.3. The kit of claim 1 , wherein a concentration of said alginate in a bioadhesive obtained by combining said first formulation and said second formulation at volume ratio of 1:9 to 25:1 claim 1 , ranges from 5 mg/ml to 100 mg/ml.4. The kit of claim 1 , wherein a concentration of said montmorillonite in a bioadhesive obtained by combining said first formulation and said second formulation at volume ratio of 1:9 to 25:1 claim 1 , ranges from 1 mg/ml to 50 mg/ml.5. The kit of claim 1 , wherein a concentration of said coupling agent in a bioadhesive obtained by combining said first formulation and said second formulation at volume ratio of 1:9 to 25:1 claim 1 , ranges from 1 mg/ml to 40 mg/ml.6. The kit of claim 1 , wherein claim 1 , in a bioadhesive obtained by combining said first formulation and said second formulation at volume ratio of 1:9 to 25:1 claim 1 , a concentration of said gelatin ranges from 200 mg/ml to 400 mg/ml claim 1 , a concentration of said alginate ranges from 20 mg/ml to 40 mg/ml claim 1 , a concentration of said ...

Подробнее
Номер записи: 100